clofazimine has been researched along with Leprosy in 321 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Leprosy: A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy." | 9.11 | Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. ( Abalos, RM; Balagon, MV; Cellona, RV; Dela Cruz, EC; Fajardo, TT; Tan, EV; Villahermosa, LG; Walsh, DS; Walsh, GP, 2004) |
| "Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ)." | 9.10 | Biochemical and hematological side effects of clofazimine in leprosy patients. ( Costa Queiroz, RH; de Souza, AM; Melchior, E; Sampaio, SV, 2002) |
| "Methaemoglobinaemia and haemolytic anaemia were the principal side-effects observed in 30 leprosy patients undergoing long-term treatment with dapsone as a single drug or as part of multidrug therapy." | 9.08 | Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients. ( Carvalho, D; Gouveia, EG; Melchior, E; Queiroz, RH; Souza, AM, 1997) |
| "During treatment of multibacillary leprosy with the combination rifampin (RMP) 600 mg, ethionamide (ETH) 500 mg, and either dapsone (DDS) or clofazimine (CLO) 100 mg, hepatotoxicity was observed in 4." | 9.05 | Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. ( Bourland, J; Davies, EM; Feracci, C; Grillone, S; Janssens, L; Pattyn, SR; Saylan, T, 1984) |
| "The effects of clofazimine on neutrophil activities such as random motility, migration to the leukoattractants endotoxin-activated serum and N-formyl-L-methionyl-L-leucyl-L-phenylalanine phagocytosis of Candida albicans, postphagocytic hexose-monophosphate shunt activity, and myeloperoxidase-mediated iodination and the effects of clofazimine on lymphocyte transformation to mitogens were assessed in vitro and after ingestion of the drug by normal individuals and patients with lepromatous leprosy." | 9.05 | Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. ( Anderson, R; Gatner, EM; Imkamp, FM; van Rensburg, CE, 1982) |
| "Patients with previously untreated borderline-lepromatous or fully lepromatous leprosy were treated with one of five clofazimine (B663) regimens: 1) 200 mg daily 6 days per week; 2) 100 mg three times weekly; 3) 300 mg weekly; 4) 600 mg every other week; and 5) 600 mg on 2 consecutive days every 4 weeks." | 9.04 | Spaced clofazimine therapy of lepromatous leprosy. ( , 1976) |
| "The usefulness of clofazimine (CLO, CAS 2030-63-9) in the treatment of mycobacterial infections with special emphasis on treatment of leprosy is critically discussed." | 8.78 | Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. ( Freerksen, E; Seydel, JK, 1992) |
| "This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy in leprosy and Mycobacterium avium complex (MAC) infection, adverse effects, drug interactions, and special considerations of clofazimine." | 8.78 | Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. ( Garrelts, JC, 1991) |
| "Dapsone hypersensitivity syndrome (DHS) is the most serious adverse reaction associated with dapsone administration and one of the major causes of death in patients with leprosy, whose standard treatment includes multidrug therapy (MDT) with dapsone, rifampicin, and clofazimine." | 7.91 | Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. ( Bao, F; Cao, J; Cao, Q; Chai, Z; Chen, S; Cheng, X; Chu, T; Duan, Q; Fu, F; Fu, X; Irwanto, A; Ke, W; Krismawati, H; Kuang, Y; Lang, X; Li, J; Li, L; Li, M; Li, W; Lin, Z; Liu, D; Liu, H; Liu, J; Liu, Q; Mi, Z; Ning, Y; Pan, Q; Shang, X; Shen, J; Shen, Y; Sun, L; Sun, Y; Wang, C; Wang, H; Wang, L; Wang, X; Wang, Y; Wang, Z; Wu, W; Xiao, B; Xiao, P; Xiong, F; Xiong, J; Xiong, L; Xiong, M; Xu, Y; Yan, L; Yang, B; Yang, J; You, J; Yu, G; Yu, W; Yue, Z; Zhan, X; Zhang, F; Zhang, G; Zhang, H; Zhang, L; Zhang, Y; Zhao, Q; Zhao, W; Zheng, H, 2019) |
| "Six male patients of lepromatous leprosy with erythema nodosum leprosum reaction (ENL) reactions diagnosed clinically and by slit skin smear were treated with aspirin and clofazimine." | 7.83 | A Traditional NSAID Aspirin along with Clofazimine in Erythema Nodosum Leprosum Reaction: Study of Six Cases. ( Sharma, PK; Singh, DK, 2016) |
| "This study aims to assess the oxidative stress in leprosy patients under multidrug therapy (MDT; dapsone, clofazimine and rifampicin), evaluating the nitric oxide (NO) concentration, catalase (CAT) and superoxide dismutase (SOD) activities, glutathione (GSH) levels, total antioxidant capacity, lipid peroxidation, and methemoglobin formation." | 7.80 | Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation. ( Batista Júnior, J; Borges, RS; Coleman, MD; Monteiro, MC; Oliveira, FR; Romão, PR; Salgado, CG; Schalcher, TR; Vieira, JL, 2014) |
| "Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin." | 7.78 | Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. ( Deps, P; Guerra, P; Nasser, S; Simon, M, 2012) |
| "To evaluate the occurrence of relapse of multibacillary leprosy after multi-drug treatment including daily rifampin." | 7.77 | Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin. ( Dacso, MM; Jacobson, RR; Prestigiacomo, JF; Scollard, DM; Stryjewska, BM, 2011) |
| "Dapsone Hypersensitivity Syndrome (DHS) occurs in approximately 2% of leprosy patients in Nepal." | 7.74 | A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. ( Pandey, B; Sapkota, BR; Shrestha, K; Walker, SL, 2008) |
| "This reports a long-term follow-up study on clinical effects of ofloxacin (OFLX)-combined therapy to 14 leprosy patients with various types and stages." | 7.74 | [Long-term follow-up of ofloxacin-combined therapy for leprosy patients]. ( Ishikawa, M; Ozaki, M, 2007) |
| "Dapsone syndrome is a rare hypersensitivity reaction to dapsone and is characterized by high fever, papular or exfoliative dermatitis, progressing to liver toxicity and generalized lymphadenopathy, resembling a mononucleosis infection." | 7.73 | Dapsone syndrome with acute renal failure during leprosy treatment: case report. ( Alves-Rodrigues, EN; Fontes, CJ; Ribeiro, LC; Silva, MD; Takiuchi, A, 2005) |
| "Clofazimine-induced crystal-storing histiocytosis is a rare but well-recognized condition in the literature." | 7.70 | Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient. ( Akaraviputh, T; Chanchairujira, T; Hargrove, NS; Kachintorn, U; Manatsathit, S; Siritanaratkul, N; Sukpanichnant, S; Thakerngpol, K, 2000) |
| "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain." | 7.68 | Severe abdominal pain in low dosage clofazimine. ( Chong, PY; Ti, TK, 1993) |
| "Side-effects of leprosy treatment with dapsone are said to be uncommon, with drug allergy occurring in only one of every several hundred patients treated with dapsone." | 7.68 | Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy. ( Ala, J; Hall, JJ; Reeve, PA, 1992) |
| "In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated." | 7.67 | Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria. ( Pieters, FA; Woonink, F; Zuidema, J, 1988) |
| "A preliminary report is presented on the finding in a patient with lepromatous leprosy relapsing after maintaining clinical inactivity and bacterial negativity with dapsone monotherapy for a period of 23 years." | 7.67 | Combined clofazimine- and dapsone-resistant leprosy. A case report. ( Bhatia, VN; Harikrishnan, S; Kar, HK, 1986) |
| "Fifteen untreated leprosy patients were given rifampicin and dapsone for seven days, and then rifampicin, dapsone and clofazimine for seven days." | 7.67 | The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. ( Bharadwaj, VP; Girdhar, BK; Mathur, A; Venkatesan, K, 1986) |
| "Little is known of the perinatal consequences of the use of clofazimine (B663, Lamprene) to treat leprosy." | 7.66 | Clofazimine in pregnancy complicated by leprosy. ( Farb, H; Pedvis-Leftick, A; West, DP, 1982) |
| "Clofazimine is a valuable drug which is used worldwide in the treatment of leprosy." | 7.66 | Clofazimine-induced ichthyosis and its treatment. ( Caver, CV, 1982) |
| "This paper records the results of treatment with clofazimine of a group of 31 patients of mixed racial origin in the United Kingdom suffering from lepromatous or borderline-lepromatous leprosy." | 7.66 | Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978. ( Browne, SG; Harman, DJ; McDougall, AC; Waudby, H, 1981) |
| "Patients of lepromatous leprosy who have evolved from the borderline type of disease are known to revert to the borderline state through a reactionary phenomenon under anti-leprosy chemotherapy with Dapsone." | 7.65 | Transformation from lepromatous to borderline leprosy under clofazimine therapy. ( Mahapatra, SB; Ramu, G, 1976) |
| "This paper summarises our clinical experience with clofazimine in the treatment of 25 cases of reactive states of lepromatous and borderline leprosy and 7 lepromatous patients not responding to dapsone." | 7.65 | Clinical trial with clofazimine in leprosy. ( Dongre, VV; Ganapati, R, 1976) |
| "Leprosy is a stigmatizing, chronic infection which degenerates the nervous system and often leads to incapacitation." | 5.56 | Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia. ( Irwan, ID; Irwanto, A; Krismawati, H; Liu, H; Liu, J; Maladan, Y; Oktavian, A; Pongtiku, A; Sitanggang, YA; Sun, Y; Tanjung, R; Wahyuni, T; Zhang, F, 2020) |
| "Dapsone resistance was found in 4 of 6 biopsies from American Samoa patients." | 5.48 | Dapsone Resistance in Leprosy Patients Originally from American Samoa, United States, 2010-2012. ( Araujo, S; Scollard, D; Stryjewska, BM; Williams, DL, 2018) |
| "The World Health Organization (WHO) recommends multidrug therapy (MDT) with rifampicin, dapsone, and clofazimine for treating leprosy, which is based on very low-quality evidence." | 5.41 | Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis. ( Bao, F; Chen, J; Dong, Y; Fan, Y; Gao, L; Ji, Z; Kong, J; Li, B; Liu, A; Liu, M; Luo, S; Ma, W; Peng, L; Song, J; Wu, X; Yang, J, 2023) |
| "It is the drug of choice for the treatment of leprosy and prophylaxis of malaria." | 5.30 | Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT. ( Barbosa, JC; de Carvalho, D; de Souza, AM; Gouveia, E; Melchior Júnior, E; Queiroz, RH, 1997) |
| "Clofazimine was administered initially 100 mg three times daily for one month and then gradually reduced to a dose of 100 mg biweekly for the last three months." | 5.27 | Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction. ( Balsara, JJ; Bulakh, PM; Burte, NP; Chandorkar, AG; Muley, MP, 1983) |
| "Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy." | 5.11 | Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. ( Abalos, RM; Balagon, MV; Cellona, RV; Dela Cruz, EC; Fajardo, TT; Tan, EV; Villahermosa, LG; Walsh, DS; Walsh, GP, 2004) |
| "Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ)." | 5.10 | Biochemical and hematological side effects of clofazimine in leprosy patients. ( Costa Queiroz, RH; de Souza, AM; Melchior, E; Sampaio, SV, 2002) |
| "Methaemoglobinaemia and haemolytic anaemia were the principal side-effects observed in 30 leprosy patients undergoing long-term treatment with dapsone as a single drug or as part of multidrug therapy." | 5.08 | Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients. ( Carvalho, D; Gouveia, EG; Melchior, E; Queiroz, RH; Souza, AM, 1997) |
| "Pyrazinamide in a dose of 1500 mg was given to 63 borderline lepromatous (BL) and lepromatous (LL) leprosy patients on different drug regimens for the initial 2 months of therapy." | 5.06 | Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report. ( Katoch, K; Ramanathan, U; Ramu, G, 1988) |
| "Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases." | 5.05 | Clofazimine: an old drug for never-ending diseases. ( Besozzi, G; Biagio, AD; Canetti, D; Codecasa, L; Comelli, A; Diaw, MM; Gaiera, G; Giacomelli, A; Intini, E; Riccardi, N; Udwadia, Z, 2020) |
| "Twenty patients of lepromatous leprosy with lepra reaction and suspected dapsone resistance were treated with tapering doses of clofazimine." | 5.05 | Clofazimine in lepra (ENL) reaction, one year clinical trial. ( Balsara, JJ; Bulakh, PM; Burte, NP; Chandorkar, AG; Muley, MP, 1983) |
| "During treatment of multibacillary leprosy with the combination rifampin (RMP) 600 mg, ethionamide (ETH) 500 mg, and either dapsone (DDS) or clofazimine (CLO) 100 mg, hepatotoxicity was observed in 4." | 5.05 | Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. ( Bourland, J; Davies, EM; Feracci, C; Grillone, S; Janssens, L; Pattyn, SR; Saylan, T, 1984) |
| "The effects of clofazimine on neutrophil activities such as random motility, migration to the leukoattractants endotoxin-activated serum and N-formyl-L-methionyl-L-leucyl-L-phenylalanine phagocytosis of Candida albicans, postphagocytic hexose-monophosphate shunt activity, and myeloperoxidase-mediated iodination and the effects of clofazimine on lymphocyte transformation to mitogens were assessed in vitro and after ingestion of the drug by normal individuals and patients with lepromatous leprosy." | 5.05 | Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. ( Anderson, R; Gatner, EM; Imkamp, FM; van Rensburg, CE, 1982) |
| "Patients with previously untreated borderline-lepromatous or fully lepromatous leprosy were treated with one of five clofazimine (B663) regimens: 1) 200 mg daily 6 days per week; 2) 100 mg three times weekly; 3) 300 mg weekly; 4) 600 mg every other week; and 5) 600 mg on 2 consecutive days every 4 weeks." | 5.04 | Spaced clofazimine therapy of lepromatous leprosy. ( , 1976) |
| "The usefulness of clofazimine (CLO, CAS 2030-63-9) in the treatment of mycobacterial infections with special emphasis on treatment of leprosy is critically discussed." | 4.78 | Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. ( Freerksen, E; Seydel, JK, 1992) |
| "This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy in leprosy and Mycobacterium avium complex (MAC) infection, adverse effects, drug interactions, and special considerations of clofazimine." | 4.78 | Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. ( Garrelts, JC, 1991) |
| "BACKGROUND: Clofazimine (CFZ) is routinely used worldwide for the treatment of leprosy and TB." | 4.31 | Extemporaneously compounded liquid formulations of clofazimine. ( Fourie, CL; Garcia-Prats, AJ; Hesseling, AC; Hoddinott, G; Jew, RK; Nahata, MC; Pande, PG; Scarim, A; Scarim, J; Schaaf, HS; Taneja, R, 2023) |
| "Dapsone hypersensitivity syndrome (DHS) is the most serious adverse reaction associated with dapsone administration and one of the major causes of death in patients with leprosy, whose standard treatment includes multidrug therapy (MDT) with dapsone, rifampicin, and clofazimine." | 3.91 | Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. ( Bao, F; Cao, J; Cao, Q; Chai, Z; Chen, S; Cheng, X; Chu, T; Duan, Q; Fu, F; Fu, X; Irwanto, A; Ke, W; Krismawati, H; Kuang, Y; Lang, X; Li, J; Li, L; Li, M; Li, W; Lin, Z; Liu, D; Liu, H; Liu, J; Liu, Q; Mi, Z; Ning, Y; Pan, Q; Shang, X; Shen, J; Shen, Y; Sun, L; Sun, Y; Wang, C; Wang, H; Wang, L; Wang, X; Wang, Y; Wang, Z; Wu, W; Xiao, B; Xiao, P; Xiong, F; Xiong, J; Xiong, L; Xiong, M; Xu, Y; Yan, L; Yang, B; Yang, J; You, J; Yu, G; Yu, W; Yue, Z; Zhan, X; Zhang, F; Zhang, G; Zhang, H; Zhang, L; Zhang, Y; Zhao, Q; Zhao, W; Zheng, H, 2019) |
| "Six male patients of lepromatous leprosy with erythema nodosum leprosum reaction (ENL) reactions diagnosed clinically and by slit skin smear were treated with aspirin and clofazimine." | 3.83 | A Traditional NSAID Aspirin along with Clofazimine in Erythema Nodosum Leprosum Reaction: Study of Six Cases. ( Sharma, PK; Singh, DK, 2016) |
| "This study aims to assess the oxidative stress in leprosy patients under multidrug therapy (MDT; dapsone, clofazimine and rifampicin), evaluating the nitric oxide (NO) concentration, catalase (CAT) and superoxide dismutase (SOD) activities, glutathione (GSH) levels, total antioxidant capacity, lipid peroxidation, and methemoglobin formation." | 3.80 | Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation. ( Batista Júnior, J; Borges, RS; Coleman, MD; Monteiro, MC; Oliveira, FR; Romão, PR; Salgado, CG; Schalcher, TR; Vieira, JL, 2014) |
| "Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin." | 3.78 | Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. ( Deps, P; Guerra, P; Nasser, S; Simon, M, 2012) |
| "To evaluate the occurrence of relapse of multibacillary leprosy after multi-drug treatment including daily rifampin." | 3.77 | Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin. ( Dacso, MM; Jacobson, RR; Prestigiacomo, JF; Scollard, DM; Stryjewska, BM, 2011) |
| "Multidrug therapy (WHO/MDT) in multibacillary leprosy consists of treatment with rifampicin, dapsone and clofazimine." | 3.75 | Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report. ( Guedes Filho, G; Guedes, WR; Oliveira, BB; Oliveira, CA; Oliveira, DA; Silva, IM, 2009) |
| "Dapsone Hypersensitivity Syndrome (DHS) occurs in approximately 2% of leprosy patients in Nepal." | 3.74 | A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. ( Pandey, B; Sapkota, BR; Shrestha, K; Walker, SL, 2008) |
| "A pale ginger cat was treated with clofazimine for feline leprosy." | 3.74 | Photosensitisation induced by clofazimine in a cat. ( Bennett, Sl, 2007) |
| "This reports a long-term follow-up study on clinical effects of ofloxacin (OFLX)-combined therapy to 14 leprosy patients with various types and stages." | 3.74 | [Long-term follow-up of ofloxacin-combined therapy for leprosy patients]. ( Ishikawa, M; Ozaki, M, 2007) |
| "The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine." | 3.74 | Adverse effects from multi-drug therapy in leprosy: a Brazilian study. ( Birshner, Rde C; Deps, PD; Guerra, P; Nasser, S; Rodrigues, LC; Simon, M, 2007) |
| "Dapsone syndrome is a rare hypersensitivity reaction to dapsone and is characterized by high fever, papular or exfoliative dermatitis, progressing to liver toxicity and generalized lymphadenopathy, resembling a mononucleosis infection." | 3.73 | Dapsone syndrome with acute renal failure during leprosy treatment: case report. ( Alves-Rodrigues, EN; Fontes, CJ; Ribeiro, LC; Silva, MD; Takiuchi, A, 2005) |
| " The patient began treatment with clofazimine, rifampicin, and dapsone, but 15 days afterwards he complained of acral edema with godet sign." | 3.73 | Remitting seronegative symmetrical synovitis with pitting edema in leprosy. ( Helling, CA; Locursio, A; Manzur, ME; Sormani de Fonseca, ML, 2006) |
| "Between 1989 and 1993, 136 multibacillary leprosy patients received a 6-week treatment regimen consisting of daily rifampicin 600 mg, ofloxacin 400 mg, clofazimine 100 mg and a weekly dose of 100 mg minocycline." | 3.71 | Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. ( Grillone, S; Pattyn, S, 2002) |
| "Clofazimine-induced crystal-storing histiocytosis is a rare but well-recognized condition in the literature." | 3.70 | Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient. ( Akaraviputh, T; Chanchairujira, T; Hargrove, NS; Kachintorn, U; Manatsathit, S; Siritanaratkul, N; Sukpanichnant, S; Thakerngpol, K, 2000) |
| "Twenty-five compounds structurally related to clofazimine were tested for their ability to inhibit the growth of Mycobacterium leprae using the kinetic method of drug evaluation in the mouse foot pad model of leprosy." | 3.68 | Activity of phenazine analogs against Mycobacterium leprae infections in mice. ( O'Sullivan, JF; Shinnick, TM; Van Landingham, RM; Walker, LL, 1993) |
| "To describe the role of the clinical pharmacist in a Hansen's disease (HD, leprosy) clinic and to describe the development, validation, and operation of a dapsone compliance monitoring program." | 3.68 | Therapeutic monitoring and pharmacist intervention in a Hansen's disease clinic. ( Danziger, LH; Fischer, JH; Hill, C; Occhipinti, DJ; Piscitelli, SC; West, DP, 1993) |
| "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain." | 3.68 | Severe abdominal pain in low dosage clofazimine. ( Chong, PY; Ti, TK, 1993) |
| "The proportion of relapses among all patients detected each year increased steadily since the initiation of the national leprosy control program in China with dapsone monotherapy in 1955, reaching 18%-24% in the more leprosy-endemic provinces along the coast." | 3.68 | Problems of leprosy relapse in China. ( Li, HY, 1993) |
| "Side-effects of leprosy treatment with dapsone are said to be uncommon, with drug allergy occurring in only one of every several hundred patients treated with dapsone." | 3.68 | Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy. ( Ala, J; Hall, JJ; Reeve, PA, 1992) |
| "In 1982, following the recommendations of a WHO study group, multidrug therapy (MDT) was introduced into French Polynesia to treat all patients suffering from active leprosy, and--only on request--those still on dapsone monotherapy." | 3.68 | Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. ( Cartel, JL; Grosset, JH; Martin, PM; Moulia-Pelat, JP; Nguyen Ngoc, L; Spiegel, A, 1992) |
| "An ambulatory treatment regimen for multibacillary leprosy, of 34 weeks duration composed of 8 weeks daily supervised rifampicin, ethionamide (ETH), dapsone (DDS) and clofazimine (CLO) followed by 26 weeks of unsupervised ETH, DDS and CLO, introduced in 1983 has been evaluated; 268 patients were followed for a mean of 4." | 3.68 | Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration. ( Bourland, J; Pattyn, SR, 1992) |
| "The feasibility and effects of a 3-year treatment using rifampicin (RFP), clofazimine (B663) and dapsone (DDS) in multibacillary leprosy patients in Yangzhou Prefecture and Dongtai County (1983-1986) are reported." | 3.68 | Effect of three-year multidrug therapy in multibacillary leprosy patients. ( Ji, F; Li, W; Luo, J; Tao, M; Wang, C; Yang, Z; Ye, G, 1990) |
| "A 24 year old man admitted to hospital with borderline lepromatous leprosy was treated with rifampicin, dapsone, and clofazimine." | 3.67 | Successful plasma exchange in type 1 leprosy reversal reaction. ( Bonhomme, J; Chalopin, JM; Lucht, F; Portier, H; Rifle, G, 1984) |
| "Fifty three multibacillary leprosy cases were treated with two regimens of MDT L1 consisting of Rifampicin, Dapsone and Ethionamide and L2 consisting of Rifampicin, Dapsone and clofazimine." | 3.67 | Evaluation of two multidrug regimen in hospitalised multibacillary cases. ( Bhate, RD; Bhate, RP; Chattopadhyay, SP; Gupta, CM, 1989) |
| "In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated." | 3.67 | Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria. ( Pieters, FA; Woonink, F; Zuidema, J, 1988) |
| "A preliminary report is presented on the finding in a patient with lepromatous leprosy relapsing after maintaining clinical inactivity and bacterial negativity with dapsone monotherapy for a period of 23 years." | 3.67 | Combined clofazimine- and dapsone-resistant leprosy. A case report. ( Bhatia, VN; Harikrishnan, S; Kar, HK, 1986) |
| "The rise in the incidence of dapsone-resistant leprosy requires new therapeutic approaches." | 3.67 | [Therapy of leprosy today]. ( Bahmer, FA; Menzel, S, 1987) |
| "Fifteen untreated leprosy patients were given rifampicin and dapsone for seven days, and then rifampicin, dapsone and clofazimine for seven days." | 3.67 | The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. ( Bharadwaj, VP; Girdhar, BK; Mathur, A; Venkatesan, K, 1986) |
| "A comparative study with 2 tier and 3 tier combination of Rifampicin, Clofazimine, DDS, INAH and Thiacetazone was conducted on fifty lepromatous leprosy cases for varying periods." | 3.66 | Multiple drug therapy--a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH and thiacetazone in lepromatous cases. ( Chaudhury, S; Ghosh, S; Hazra, S; Kundu, SK, 1981) |
| "The practical problems related to dapsone monotherapy for a prolonged period to infectious leprosy patients are well known to the scientific community and combined treatment of dapsone with clofazimine, rifampicin or prothionamide has been successfully carried out by several workers in hospitalised leprosy patients." | 3.66 | Field application of combined therapy for infectious leprosy cases. A feasibility study in Bombay. ( Ganapati, R; Naik, SS; Revankar, CR, 1983) |
| "Oral zinc sulfate was tried in Eight cases of recurrent Erythema Nodosum Leprosum." | 3.66 | Oral zinc in recurrent Erythema Nodosum Leprosum reaction. ( Bumb, RA; Mangal, HN; Mathur, NK, 1983) |
| "Little is known of the perinatal consequences of the use of clofazimine (B663, Lamprene) to treat leprosy." | 3.66 | Clofazimine in pregnancy complicated by leprosy. ( Farb, H; Pedvis-Leftick, A; West, DP, 1982) |
| "Clofazimine is a valuable drug which is used worldwide in the treatment of leprosy." | 3.66 | Clofazimine-induced ichthyosis and its treatment. ( Caver, CV, 1982) |
| "This paper records the results of treatment with clofazimine of a group of 31 patients of mixed racial origin in the United Kingdom suffering from lepromatous or borderline-lepromatous leprosy." | 3.66 | Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978. ( Browne, SG; Harman, DJ; McDougall, AC; Waudby, H, 1981) |
| "Thirty three leprosy patients in reaction were treated with a combination of Metronidazole--Diethyl carbamazine citrate--Chloroquin which was reinforced either with prednisolone and/or Clofazimine in some, depending on the clinical state." | 3.66 | Multi-drug treatment for reactions in leprosy. ( Razack, EM; Zahra, A, 1981) |
| "Three out of 30 patients of leprosy getting clofazimine therapy developed severe gastrointestinal side effects following the therapy in the dose of 100 mg after one month, eight months and five weeks respectively." | 3.66 | Gastro-intestinal side effects of clofazimine. ( Garg, BR; Hameedulla, A; Lal, S, 1981) |
| " Reactive episodes continue to be a serious complication, but the availability of thalidomide to control erythema nodosum leprosum has markedly improved the prognosis." | 3.65 | The diagnosis and treatment of leprosy. ( Jacobson, RR; Trautman, JR, 1976) |
| "Patients of lepromatous leprosy who have evolved from the borderline type of disease are known to revert to the borderline state through a reactionary phenomenon under anti-leprosy chemotherapy with Dapsone." | 3.65 | Transformation from lepromatous to borderline leprosy under clofazimine therapy. ( Mahapatra, SB; Ramu, G, 1976) |
| "This paper summarises our clinical experience with clofazimine in the treatment of 25 cases of reactive states of lepromatous and borderline leprosy and 7 lepromatous patients not responding to dapsone." | 3.65 | Clinical trial with clofazimine in leprosy. ( Dongre, VV; Ganapati, R, 1976) |
| "The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR), designed to evaluate the effectiveness of a six-months regimen, assessed the adverse effects caused by the drugs." | 2.87 | Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach. ( Bührer-Sékula, S; Cruz, RCDS; Gonçalves, HS; Moraes, MEA; Penna, GO; Penna, MLF; Pontes, MAA; Stefani, MMA; Talhari, S, 2018) |
| "Type 2 lepra reaction (T2R) is a difficult-to-manage condition in leprosy, and an effective and safe steroid-sparing agent is needed for its management." | 2.80 | Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study. ( Bandyopadhyay, D; Das, NK; Roy, K; Sil, A, 2015) |
| "Incidence of neuritis associated with RR as well as isolated neuritis was similar in both groups." | 2.67 | Reversal reaction in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w. ( Beena, KR; Kar, HK; Misra, RS; Mukherjee, A; Mukherjee, R; Nair, NS; Parida, SK; Sharma, AK; Walia, R; Zaheer, SA, 1993) |
| " In patients who received the same drug regimens but with a reduced dosage of ethionamide to 5 mg/k bodyweight, the incidence of hepatitis was significantly lower but the relapse rate was 7." | 2.67 | Treatment of multibacillary leprosy with a regimen of 13 weeks duration. ( Groenen, G; Janssens, L; Kuykens, L; Mputu, LB; Pattyn, SR, 1992) |
| "Leprosy is a chronic infectious disease caused my Mycobacterium leprae that primarily affects peripheral nervous system and extremities and is prevalent in tropical countries." | 2.66 | Metabolism and interactions of antileprosy drugs. ( George, J, 2020) |
| "Histoid leprosy is a rare variant of leprosy with a unique clinical presentation and bacilli rich histology." | 2.66 | Treatment of histoid leprosy: a lack of consensus. ( Bartos, G; Combs, A; Rivlin, D; Sheuring, R, 2020) |
| "Leprosy is present in more than 100 countries, where it remains a major cause of peripheral neuropathy and disability." | 2.55 | Multidrug therapy for leprosy: a game changer on the path to elimination. ( Aerts, A; Kawuma, J; Kita, E; Saunderson, P; Smith, CS; Virmond, M, 2017) |
| "Leprosy is a chronic disease with many clinical manifestations, which affect mainly the skin, the peripheral nerves, mucosa of the upper respiratory tract and the eyes." | 2.53 | Leprosy – an old infectious disease with unsolved matters. ( Stock, I, 2016) |
| "Leprosy is an infectious disease that has now been reported for more than 2000 years." | 2.52 | Update on the epidemiology, diagnosis, and treatment of leprosy. ( Aubry, A; Cambau, E; Reibel, F, 2015) |
| "Leprosy is a granulomatous disease affecting the skin and peripheral nerves caused by Mycobacterium leprae." | 2.44 | [Hansen's disease: case report and review of literature]. ( Concha R, M; Cossio T, ML; Fich S, F; González B, S; Pérez C, C; Salazar S, I, 2008) |
| "The diagnosis of leprosy is frequently not considered, with resultant pathological and psychological problems for patients." | 2.41 | Update on leprosy. ( Lockwood, DN; Marlowe, SN, 2001) |
| "Current treatment of leprosy involves use of 3 drugs: rifampicin (rifampin); clofazimine; and dapsone." | 2.41 | Leprosy. Recognition and treatment. ( Ramos-e-Silva, M; Rebello, PF, 2001) |
| " In many cases dose and intervals were based on WHO protocol, however smaller dosage was used in some cases." | 2.40 | [Chemotherapy of Hansen's disease in Japan--present status]. ( Goto, M; Kitajima, S; Miyagi, S; Takizawa, H, 1998) |
| "Leprosy is a stigmatizing, chronic infection which degenerates the nervous system and often leads to incapacitation." | 1.56 | Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia. ( Irwan, ID; Irwanto, A; Krismawati, H; Liu, H; Liu, J; Maladan, Y; Oktavian, A; Pongtiku, A; Sitanggang, YA; Sun, Y; Tanjung, R; Wahyuni, T; Zhang, F, 2020) |
| "Dapsone resistance was found in 4 of 6 biopsies from American Samoa patients." | 1.48 | Dapsone Resistance in Leprosy Patients Originally from American Samoa, United States, 2010-2012. ( Araujo, S; Scollard, D; Stryjewska, BM; Williams, DL, 2018) |
| "To assess the adverse effects of multi drug therapy (MDT) in leprosy patients." | 1.37 | Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). ( Dey, V; Dulhani, N; Nel, B; Singh, H; Tiwari, P, 2011) |
| "Leprosy is a rare cause of neuropathy in Europeans." | 1.35 | [Sensory-motor neuropathy: a slow and misleading case of leprosy]. ( Andre, P; Camu, W; Flageul, B; Gabelle, A; Vallat, JM, 2008) |
| "Leprosy is well controlled in Hong Kong but continued surveillance is required to detect relapses and to ensure good patient compliance with treatment." | 1.33 | Epidemiology of leprosy and response to treatment in Hong Kong. ( Ho, CK; Lo, KK, 2006) |
| "Leprosy is an ancient disease, which was treated by local application of chaulmoogra/hydnocarpus oil during prechemotherapeutic era." | 1.33 | Multidrug therapy in leprosy. ( Arif, MA; Manglani, PR, 2006) |
| "Areas of low endemicity of Hansen's disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections." | 1.32 | Short report: Treatment failure in Hansen's disease. ( Joyce, MP; Longfield, RN; Murray, CK, 2003) |
| " The results of the study therefore reveal that patients undergoing therapy had significantly greater DNA damage than untreated patients, indicating bacterial infection and drug therapy as the causal factors, since lepromatous-type disease is the more severe form with the patients having lower resistance to Mycobacterium leprae and requiring heavier and prolonged dosage of antibiotics." | 1.32 | DNA damage studies in untreated and treated leprosy patients. ( Gandhi, G; Singh, B, 2004) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| "It is the drug of choice for the treatment of leprosy and prophylaxis of malaria." | 1.30 | Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT. ( Barbosa, JC; de Carvalho, D; de Souza, AM; Gouveia, E; Melchior Júnior, E; Queiroz, RH, 1997) |
| "In the present study, we evaluated the in vivo anti-Mycobacterium leprae activities of KRM-1648 (KRM) given at long intervals in combination with ofloxacin (OFLX), clofazimine (CFZ), and dapsone (DDS)." | 1.30 | Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic ( Maw, WW; Saito, H; Sato, K; Tomioka, H, 1997) |
| "In this study, the in vitro and in vivo anti-Mycobacterium leprae activity of the newly developed benzoxazinorifamycin, KRM-1648, in combination with clofazimine (CFZ) or dapsone (DDS) was evaluated." | 1.29 | Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice. ( Dekio, S; Saito, H; Sato, K; Tomioka, H, 1994) |
| "The difficulty in treating leprosy may be partly ascribable to decreased phagocytic OH X generation, which in leprosy patients is apparently due to the uptake of Hansen bacillus-derived SOD." | 1.27 | Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. ( Miyachi, Y; Niwa, Y; Ozaki, M; Sakane, T, 1984) |
| "Clofazimine was administered in different doses over a period of 12 months." | 1.27 | The effect of clofazimine on liver function tests in lepra reaction (ENL). ( Bulakh, PM; Burte, NP; Chandorkar, AG; Kowale, CN; Ranade, SM, 1983) |
| "Clofazimine was administered initially 100 mg three times daily for one month and then gradually reduced to a dose of 100 mg biweekly for the last three months." | 1.27 | Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction. ( Balsara, JJ; Bulakh, PM; Burte, NP; Chandorkar, AG; Muley, MP, 1983) |
| " ENL was also more frequent in regimens C and D and was not prevented by CLO in the dosage used." | 1.27 | Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions. ( Coussens, L; Groenen, G; Janssens, L; Kayembe, T; Nollet, E; Pattyn, SR, 1986) |
| "Only in lepromatous cases was complete ageusia seen (9." | 1.27 | Electrogustometry in Hansen's disease (study of 225 cases). ( Chaturvedi, VN; Jain, SK; Raizada, RM; Rathi, SS, 1986) |
| " The initial dosage of either of the drugs was 300 mg daily administered in divided doses of 100 mg three times a day." | 1.26 | Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine. ( Girdhar, A; Ramu, G, 1979) |
| "In rifampin-treated immunosuppressed animals the survival half-life of solid bacilli, in the absence of host immunity, was 12-13 days." | 1.26 | Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection. ( Banerjee, DK; Hilson, GR; Holmes, IB, 1976) |
| " The common side effect in all cases consisted of red and dark skin pigmentation of varying intensity occuring within 10 weeks of the commencement of therapy." | 1.26 | Side effects of clofazimine therapy. ( Iyer, GG; Ramu, G, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 179 (55.76) | 18.7374 |
| 1990's | 55 (17.13) | 18.2507 |
| 2000's | 47 (14.64) | 29.6817 |
| 2010's | 28 (8.72) | 24.3611 |
| 2020's | 12 (3.74) | 2.80 |
| Authors | Studies |
|---|---|
| Bera, S | 1 |
| Mondal, D | 1 |
| Chakraborty, A | 1 |
| Ghosh, R | 1 |
| Biswas, A | 1 |
| Chavhan, SD | 1 |
| Jawade, S | 1 |
| Yang, J | 2 |
| Kong, J | 1 |
| Li, B | 1 |
| Ji, Z | 1 |
| Liu, A | 1 |
| Chen, J | 1 |
| Liu, M | 1 |
| Fan, Y | 1 |
| Peng, L | 1 |
| Song, J | 1 |
| Wu, X | 1 |
| Gao, L | 1 |
| Ma, W | 1 |
| Dong, Y | 1 |
| Luo, S | 1 |
| Bao, F | 2 |
| Taneja, R | 1 |
| Nahata, MC | 1 |
| Scarim, J | 1 |
| Pande, PG | 1 |
| Scarim, A | 1 |
| Hoddinott, G | 1 |
| Fourie, CL | 1 |
| Jew, RK | 1 |
| Schaaf, HS | 1 |
| Hesseling, AC | 1 |
| Garcia-Prats, AJ | 1 |
| George, J | 2 |
| Riccardi, N | 1 |
| Giacomelli, A | 1 |
| Canetti, D | 1 |
| Comelli, A | 1 |
| Intini, E | 1 |
| Gaiera, G | 1 |
| Diaw, MM | 1 |
| Udwadia, Z | 1 |
| Besozzi, G | 1 |
| Codecasa, L | 1 |
| Biagio, AD | 1 |
| Bartos, G | 1 |
| Sheuring, R | 1 |
| Combs, A | 1 |
| Rivlin, D | 1 |
| Lee, JH | 1 |
| An, HK | 1 |
| Sohn, MG | 1 |
| Kivela, P | 1 |
| Oh, S | 1 |
| Krismawati, H | 2 |
| Irwanto, A | 2 |
| Pongtiku, A | 1 |
| Irwan, ID | 1 |
| Maladan, Y | 1 |
| Sitanggang, YA | 1 |
| Wahyuni, T | 1 |
| Tanjung, R | 1 |
| Sun, Y | 2 |
| Liu, H | 2 |
| Zhang, F | 2 |
| Oktavian, A | 1 |
| Liu, J | 3 |
| Lavania, M | 1 |
| Darlong, J | 1 |
| Singh, I | 1 |
| Ahuja, M | 1 |
| Turankar, RP | 1 |
| Pathak, VK | 1 |
| Kumar, A | 1 |
| Nathan, R | 1 |
| Sengupta, U | 2 |
| Sharma, A | 1 |
| Pai, VV | 4 |
| Mhatre, M | 1 |
| Cerqueira, SRPS | 1 |
| Deps, PD | 2 |
| Cunha, DV | 1 |
| Bezerra, NVF | 1 |
| Barroso, DH | 1 |
| Pinheiro, ABS | 1 |
| Pillegi, GS | 1 |
| Repsold, TAR | 1 |
| Kurizky, PS | 1 |
| Collin, SM | 1 |
| Gomes, CM | 1 |
| Smith, CS | 1 |
| Aerts, A | 1 |
| Saunderson, P | 1 |
| Kawuma, J | 1 |
| Kita, E | 1 |
| Virmond, M | 1 |
| Bass, M | 1 |
| Foster, K | 1 |
| Studdiford, J | 1 |
| Labuda, SM | 1 |
| Schieffelin, JS | 1 |
| Shaffer, JG | 1 |
| Stryjewska, BM | 3 |
| Kar, HK | 5 |
| Gupta, L | 1 |
| Sharma, PK | 1 |
| Singh, DK | 1 |
| Cruz, RCDS | 1 |
| Bührer-Sékula, S | 1 |
| Penna, GO | 1 |
| Moraes, MEA | 1 |
| Gonçalves, HS | 1 |
| Stefani, MMA | 1 |
| Penna, MLF | 1 |
| Pontes, MAA | 1 |
| Talhari, S | 2 |
| Stock, I | 1 |
| Williams, DL | 2 |
| Araujo, S | 1 |
| Scollard, D | 1 |
| Wang, Z | 1 |
| Wang, C | 2 |
| Sun, L | 1 |
| Zhang, H | 1 |
| Yu, G | 1 |
| Mi, Z | 1 |
| Li, J | 3 |
| Li, L | 1 |
| Zhao, Q | 1 |
| Yue, Z | 1 |
| Zhao, W | 1 |
| Yu, W | 1 |
| Cao, J | 1 |
| Xiong, F | 1 |
| Wang, Y | 2 |
| Chai, Z | 1 |
| Cheng, X | 1 |
| Zhang, Y | 1 |
| Fu, F | 1 |
| Lang, X | 1 |
| Wang, X | 1 |
| Fu, X | 1 |
| You, J | 1 |
| Pan, Q | 1 |
| Chu, T | 1 |
| Liu, D | 1 |
| Chen, S | 1 |
| Shen, J | 1 |
| Yan, L | 2 |
| Zhang, G | 1 |
| Xiong, L | 1 |
| Ke, W | 1 |
| Li, M | 2 |
| Ning, Y | 1 |
| Xiong, J | 1 |
| Xiong, M | 1 |
| Yang, B | 1 |
| Duan, Q | 1 |
| Wang, H | 1 |
| Li, W | 3 |
| Kuang, Y | 1 |
| Wang, L | 1 |
| Cao, Q | 1 |
| Xiao, P | 1 |
| Xiao, B | 1 |
| Zhang, L | 1 |
| Lin, Z | 1 |
| Shen, Y | 1 |
| Wu, W | 1 |
| Zheng, H | 1 |
| Zhan, X | 1 |
| Shang, X | 1 |
| Xu, Y | 1 |
| Liu, Q | 1 |
| Bishnoi, A | 1 |
| Chatterjee, D | 1 |
| Narang, T | 1 |
| Dogra, S | 1 |
| Bhaumik, S | 1 |
| Ker, KJ | 1 |
| Pan, JY | 1 |
| Lui, NL | 1 |
| Tey, HL | 1 |
| Schalcher, TR | 1 |
| Borges, RS | 1 |
| Coleman, MD | 1 |
| Batista Júnior, J | 1 |
| Salgado, CG | 1 |
| Vieira, JL | 1 |
| Romão, PR | 1 |
| Oliveira, FR | 1 |
| Monteiro, MC | 1 |
| Marcos, LA | 1 |
| Conerly, S | 1 |
| Walker, S | 1 |
| Roy, K | 1 |
| Sil, A | 1 |
| Das, NK | 1 |
| Bandyopadhyay, D | 1 |
| Reibel, F | 1 |
| Cambau, E | 1 |
| Aubry, A | 1 |
| Bharucha, T | 1 |
| Lockwood, D | 2 |
| Medeiros, S | 1 |
| Catorze, MG | 1 |
| Vieira, MR | 1 |
| Gabelle, A | 1 |
| Vallat, JM | 1 |
| Flageul, B | 3 |
| Andre, P | 1 |
| Camu, W | 1 |
| Sapkota, BR | 1 |
| Shrestha, K | 1 |
| Pandey, B | 1 |
| Walker, SL | 1 |
| Mendonça, VA | 1 |
| Costa, RD | 1 |
| Lyon, S | 1 |
| Penido, RA | 1 |
| Borges, VO | 1 |
| Bretas, TL | 1 |
| Antunes, CM | 1 |
| Teixeira, MM | 1 |
| Teixeira, AL | 1 |
| Silva, IM | 1 |
| Oliveira, CA | 1 |
| Guedes, WR | 1 |
| Oliveira, BB | 1 |
| Oliveira, DA | 1 |
| Guedes Filho, G | 1 |
| Sheetal, S | 1 |
| Arvind, C | 1 |
| Levis, WR | 2 |
| Spencer, TI | 1 |
| Ladizinski, B | 1 |
| Chauhan, S | 1 |
| Wakhlu, A | 1 |
| Agarwal, V | 1 |
| Velayati, AA | 1 |
| Farnia, P | 1 |
| Khalizadeh, S | 1 |
| Farahbod, AM | 1 |
| Hasanzadh, M | 1 |
| Sheikolslam, MF | 1 |
| Singh, H | 1 |
| Nel, B | 1 |
| Dey, V | 1 |
| Tiwari, P | 1 |
| Dulhani, N | 1 |
| Sekar, B | 2 |
| Arunagiri, K | 2 |
| Kumar, BN | 1 |
| Narayanan, S | 1 |
| Menaka, K | 1 |
| Oommen, PK | 1 |
| Dacso, MM | 1 |
| Jacobson, RR | 3 |
| Scollard, DM | 1 |
| Prestigiacomo, JF | 1 |
| Cholo, MC | 1 |
| Steel, HC | 1 |
| Fourie, PB | 1 |
| Germishuizen, WA | 1 |
| Anderson, R | 4 |
| Lockwood, DN | 2 |
| Cunha, Mda G | 1 |
| Deps, P | 1 |
| Guerra, P | 2 |
| Nasser, S | 2 |
| Simon, M | 2 |
| Costa Queiroz, RH | 1 |
| de Souza, AM | 2 |
| Sampaio, SV | 1 |
| Melchior, E | 3 |
| Elangeswaran, N | 1 |
| Jayarama, E | 1 |
| Rajendran, M | 1 |
| Kumar, SS | 1 |
| Vijayaraghavan, R | 1 |
| Anandan, D | 1 |
| Pattyn, S | 2 |
| Grillone, S | 4 |
| Murray, CK | 1 |
| Joyce, MP | 1 |
| Longfield, RN | 1 |
| Shaw, IN | 2 |
| Christian, M | 2 |
| Jesudasan, K | 2 |
| Kurian, N | 1 |
| Rao, GS | 2 |
| BROWNE, SG | 10 |
| HOGENZEIL, LM | 2 |
| HOGERZEIL, LM | 3 |
| BARRY, VC | 1 |
| CONALTY, ML | 1 |
| Queiroz, RH | 3 |
| Pereira, RC | 1 |
| Gotardo, MA | 1 |
| Cordeiro, DS | 1 |
| Villahermosa, LG | 1 |
| Fajardo, TT | 1 |
| Abalos, RM | 1 |
| Cellona, RV | 1 |
| Balagon, MV | 1 |
| Dela Cruz, EC | 1 |
| Tan, EV | 1 |
| Walsh, GP | 2 |
| Walsh, DS | 1 |
| Aranda, J | 1 |
| Hoang, MP | 1 |
| Cohen, JB | 1 |
| Gandhi, G | 1 |
| Singh, B | 1 |
| Sunderkötter, CH | 1 |
| Lan Ma, H | 1 |
| Ganapati, R | 6 |
| Biswas, SK | 1 |
| Alves-Rodrigues, EN | 2 |
| Ribeiro, LC | 2 |
| Silva, MD | 2 |
| Takiuchi, A | 2 |
| Fontes, CJ | 2 |
| Helling, CA | 1 |
| Locursio, A | 1 |
| Manzur, ME | 1 |
| Sormani de Fonseca, ML | 1 |
| Rabel-Filho, OC | 1 |
| Martini-Filho, D | 1 |
| Roca, B | 1 |
| Ho, CK | 1 |
| Lo, KK | 1 |
| Goto, M | 2 |
| Nogami, R | 1 |
| Hatano, K | 1 |
| Okano, Y | 1 |
| Ishii, N | 1 |
| Gidoh, M | 2 |
| Ishida, Y | 1 |
| Ozaki, M | 4 |
| Yamazaki, T | 1 |
| Matsuoka, M | 2 |
| Firooz, A | 1 |
| Burns, J | 1 |
| Manglani, PR | 1 |
| Arif, MA | 1 |
| Lewallen, S | 1 |
| Courtright, P | 1 |
| Bennett, Sl | 1 |
| Ishikawa, M | 1 |
| Birshner, Rde C | 1 |
| Rodrigues, LC | 1 |
| Concha R, M | 1 |
| Cossio T, ML | 1 |
| Salazar S, I | 1 |
| Fich S, F | 1 |
| Pérez C, C | 1 |
| González B, S | 1 |
| Kroger, A | 1 |
| Pannikar, V | 1 |
| Htoon, MT | 1 |
| Jamesh, A | 1 |
| Katoch, K | 3 |
| Krishnamurthy, P | 1 |
| Ramalingam, K | 1 |
| Jianping, S | 1 |
| Jadhav, V | 1 |
| Gupte, MD | 1 |
| Manickam, P | 1 |
| Abide, JM | 1 |
| Webb, RM | 1 |
| Jones, HL | 1 |
| Young, L | 1 |
| Niwa, Y | 2 |
| Sakane, T | 1 |
| Miyachi, Y | 1 |
| Ramu, G | 13 |
| Desikan, KV | 5 |
| Kundu, SK | 2 |
| Ghosh, S | 2 |
| Hazra, S | 1 |
| Chaudhury, S | 1 |
| Seshadri, PS | 2 |
| Ravi, NT | 1 |
| Hooper, M | 1 |
| Purohit, MG | 1 |
| Jopling, WH | 4 |
| McDougall, AC | 4 |
| Jones, RL | 1 |
| Levy, L | 3 |
| Sansarricq, H | 1 |
| Burte, NP | 3 |
| Chandorkar, AG | 3 |
| Muley, MP | 2 |
| Balsara, JJ | 2 |
| Bulakh, PM | 3 |
| Waters, MF | 4 |
| Prabhakar, MC | 1 |
| Appa Rao, AV | 1 |
| Krishna, DR | 1 |
| Ramanakar, TV | 1 |
| Moschella, SL | 1 |
| Pattyn, SR | 11 |
| Janssens, L | 5 |
| Bourland, J | 3 |
| Saylan, T | 2 |
| Davies, EM | 1 |
| Feracci, C | 1 |
| Keeler, RF | 1 |
| Lucht, F | 1 |
| Rifle, G | 1 |
| Portier, H | 1 |
| Chalopin, JM | 1 |
| Bonhomme, J | 1 |
| Nêgrel, AD | 1 |
| Chovet, M | 1 |
| Baquillon, G | 1 |
| Lagadec, R | 1 |
| Riley, DN | 1 |
| Le, KZ | 1 |
| Nguen, TD | 1 |
| Smirnov, VS | 1 |
| Nguen, N | 1 |
| Nguen, KA | 1 |
| Revankar, CR | 2 |
| Naik, SS | 1 |
| Mathur, NK | 2 |
| Bumb, RA | 1 |
| Mangal, HN | 1 |
| Kowale, CN | 1 |
| Ranade, SM | 1 |
| Valdes-Portela, A | 1 |
| Vazquez, AM | 1 |
| Finlay, CM | 1 |
| Moore, VJ | 1 |
| Duncan, ME | 1 |
| Oakey, RE | 1 |
| Winsley, BE | 1 |
| Brown, KE | 1 |
| Warndorff-van Diepen, T | 1 |
| Beeching, NJ | 1 |
| Ellis, CJ | 1 |
| Brazin, SA | 1 |
| Rees, RJ | 1 |
| Lang, WR | 1 |
| Cunha, MG | 1 |
| Barros, ML | 1 |
| Gadelha, AD | 1 |
| Binford, CH | 1 |
| Meyers, WM | 1 |
| van Rensburg, CE | 1 |
| Gatner, EM | 2 |
| Imkamp, FM | 4 |
| Farb, H | 1 |
| West, DP | 2 |
| Pedvis-Leftick, A | 1 |
| Caver, CV | 1 |
| Peters, JH | 1 |
| Hamme, KJ | 1 |
| Gordon, GR | 1 |
| Guha, PK | 1 |
| Ghosh, M | 1 |
| Bharadwaj, VP | 3 |
| Sritharan, V | 1 |
| Venkatesan, K | 3 |
| Girdhar, A | 2 |
| Kumar, B | 1 |
| Bahadur, B | 1 |
| Broor, SL | 1 |
| Kaur, S | 3 |
| Gangwar, DN | 1 |
| Malik, AK | 1 |
| Harman, DJ | 1 |
| Waudby, H | 1 |
| Paul, S | 1 |
| Rose, ET | 1 |
| Pannikar, VK | 1 |
| Arunthathi, S | 2 |
| Dubey, GK | 1 |
| Joglekar, VK | 1 |
| Hardas, UD | 1 |
| Chaubey, BS | 1 |
| Razack, EM | 1 |
| Zahra, A | 1 |
| Lal, S | 1 |
| Garg, BR | 1 |
| Hameedulla, A | 1 |
| Leiker, DL | 6 |
| Dutta, RK | 2 |
| Ross, WF | 1 |
| Vasireddi, SS | 1 |
| Chowdappa, J | 1 |
| Choudhury, HS | 1 |
| Vu, TT | 1 |
| Hoang, TL | 1 |
| Nguyen, DQ | 1 |
| Ho, ML | 1 |
| Nguyen, DH | 1 |
| Le, TH | 1 |
| Dang, DT | 1 |
| Nguyen, QA | 1 |
| Le, TP | 1 |
| Tran, HK | 1 |
| Jackson, T | 1 |
| Mendis, S | 1 |
| Somasiri, KG | 1 |
| Chularatna, W | 1 |
| Saito, H | 2 |
| Tomioka, H | 2 |
| Sato, K | 2 |
| Dekio, S | 1 |
| Ghys, P | 3 |
| Tshilumba, K | 1 |
| Kuykens, L | 2 |
| Karibushi, N | 1 |
| Denis, P | 1 |
| Van Landingham, RM | 1 |
| Walker, LL | 1 |
| O'Sullivan, JF | 2 |
| Shinnick, TM | 1 |
| Sharma, AK | 1 |
| Misra, RS | 3 |
| Beena, KR | 1 |
| Zaheer, SA | 1 |
| Mukherjee, R | 3 |
| Mukherjee, A | 3 |
| Parida, SK | 1 |
| Walia, R | 1 |
| Nair, NS | 1 |
| Piscitelli, SC | 1 |
| Occhipinti, DJ | 1 |
| Danziger, LH | 1 |
| Hill, C | 2 |
| Fischer, JH | 1 |
| Chong, PY | 1 |
| Ti, TK | 1 |
| Li, HY | 2 |
| Lim, JT | 1 |
| Tan, T | 1 |
| Sticht-Groh, V | 1 |
| Bretzel, G | 1 |
| Kohli, MM | 1 |
| Ganguly, NK | 2 |
| Sharma, VK | 3 |
| O'Connor, R | 1 |
| O'Kennedy, R | 2 |
| Bhargava, P | 1 |
| Kuldeep, CM | 1 |
| Naafs, B | 2 |
| Souza, AM | 1 |
| Gouveia, EG | 1 |
| Carvalho, D | 1 |
| Melchior Júnior, E | 1 |
| Gouveia, E | 1 |
| Barbosa, JC | 1 |
| de Carvalho, D | 1 |
| Maw, WW | 1 |
| Ji, B | 1 |
| Miyagi, S | 1 |
| Takizawa, H | 1 |
| Kitajima, S | 1 |
| Moubasher, AD | 1 |
| Kamel, NA | 1 |
| Zedan, H | 1 |
| Raheem, DD | 1 |
| Barral-Netto, M | 1 |
| Santos, S | 1 |
| Santos, I | 1 |
| von Sohsten, R | 1 |
| Bittencourt, AL | 1 |
| Carvalho, EM | 1 |
| Barral, A | 1 |
| Waters, M | 1 |
| MacLean, S | 1 |
| Stietenroth, K | 1 |
| Prange, H | 1 |
| Vides, EA | 1 |
| Cabrera, A | 1 |
| Ahern, KP | 1 |
| Mysore, V | 1 |
| al-Suwaid, AR | 1 |
| Sharma, P | 2 |
| Kaur, H | 2 |
| Rani, R | 2 |
| Ebenezer, GJ | 1 |
| Job, A | 1 |
| Abraham, S | 1 |
| Rao, PS | 1 |
| Job, CK | 2 |
| Bulchand, HO | 1 |
| Sukpanichnant, S | 1 |
| Hargrove, NS | 1 |
| Kachintorn, U | 1 |
| Manatsathit, S | 1 |
| Chanchairujira, T | 1 |
| Siritanaratkul, N | 1 |
| Akaraviputh, T | 1 |
| Thakerngpol, K | 1 |
| Winter, CA | 1 |
| Hsu, S | 1 |
| Singh, HB | 1 |
| Natrajan, M | 1 |
| Sharma, RK | 1 |
| Gupta, UD | 1 |
| Sharma, VD | 1 |
| Singh, D | 1 |
| Chauhan, DS | 1 |
| Srivastava, K | 1 |
| Katoch, VM | 1 |
| Roche, PW | 2 |
| Neupane, KD | 2 |
| Failbus, SS | 2 |
| Butlin, CR | 1 |
| Sen, P | 1 |
| Ranjan, R | 1 |
| Middleton, JR | 1 |
| Natrajan, MM | 1 |
| Kavitha, M | 1 |
| Kashiwabara, Y | 1 |
| Namisato, M | 1 |
| Marlowe, SN | 1 |
| Ramos-e-Silva, M | 1 |
| Rebello, PF | 1 |
| Alto, WA | 1 |
| Ohman, L | 1 |
| Wahlberg, I | 1 |
| Hentschel, B | 1 |
| Jolliffe, DS | 1 |
| Faber, WR | 1 |
| Yawalkar, SJ | 1 |
| Vischer, W | 1 |
| Bryceson, A | 1 |
| Ellis, BP | 1 |
| Holmes, IB | 1 |
| Banerjee, DK | 3 |
| Hilson, GR | 1 |
| Taylor, PM | 1 |
| Alexander, R | 1 |
| Mason, GH | 1 |
| Ellis-Pegler, RB | 1 |
| Arthur, JF | 1 |
| Balakrishnan, S | 4 |
| Barrett, DF | 1 |
| Trautman, JR | 2 |
| Mahapatra, SB | 1 |
| Irani, SJ | 1 |
| Iyer, CG | 2 |
| Hazra, SK | 1 |
| Choudhury, S | 1 |
| Dongre, VV | 1 |
| Theophilus, S | 1 |
| Iyer, GG | 1 |
| Karat, AB | 2 |
| Prabhudas, N | 1 |
| Ramanujam, K | 2 |
| Rollier, MT | 1 |
| Rollier, R | 1 |
| Saerens, EJ | 1 |
| Dockx, P | 1 |
| Gatti, JC | 1 |
| Languillon, J | 1 |
| Azulay, RD | 1 |
| da Silva, NC | 1 |
| Zeo, A | 1 |
| de Jesus, M | 1 |
| Franca, CB | 1 |
| Beiguelman, B | 1 |
| Ahrens, TF | 1 |
| Pettit, JH | 1 |
| Ridley, DS | 1 |
| Glaus, L | 1 |
| Steenbergen, GJ | 1 |
| Pfaltzgraff, RE | 3 |
| Plock, H | 1 |
| Reeve, PA | 1 |
| Ala, J | 1 |
| Hall, JJ | 1 |
| Cartel, JL | 1 |
| Spiegel, A | 1 |
| Nguyen Ngoc, L | 1 |
| Moulia-Pelat, JP | 1 |
| Martin, PM | 1 |
| Grosset, JH | 2 |
| Freerksen, E | 2 |
| Seydel, JK | 1 |
| Becx-Bleumink, M | 2 |
| Gillis, TP | 1 |
| Fiallo, P | 1 |
| Gelber, RH | 2 |
| Izumi, S | 1 |
| Groenen, G | 4 |
| Mputu, LB | 1 |
| Oommen, T | 2 |
| Natu, MV | 1 |
| Wilfred, D | 1 |
| Britton, WJ | 1 |
| Cho, SN | 1 |
| Theuvenet, WJ | 1 |
| Blok, LM | 1 |
| Bloos, LJ | 1 |
| van den Berg, G | 1 |
| Patki, AH | 2 |
| Gilbody, JS | 1 |
| Garrelts, JC | 1 |
| Stone, OJ | 1 |
| Vignon-Pennamen, MD | 1 |
| Wallach, D | 2 |
| Pennec, J | 1 |
| Cottenot, F | 2 |
| Ellard, GA | 4 |
| Aoyagi, T | 1 |
| Toyoda, T | 1 |
| Ye, G | 1 |
| Yang, Z | 1 |
| Tao, M | 1 |
| Luo, J | 1 |
| Ji, F | 1 |
| O'Sullivan, S | 1 |
| Corcoran, M | 1 |
| Byrne, M | 1 |
| McGrath, S | 1 |
| Ramanathan, U | 1 |
| Jadhav, VH | 1 |
| Mehta, JM | 1 |
| Deverchin, J | 1 |
| Chatterjee, G | 1 |
| Vaishnavi, C | 1 |
| Holdiness, MR | 1 |
| Chopra, NK | 1 |
| Agarwal, JS | 1 |
| Pandya, PG | 1 |
| Chattopadhyay, SP | 1 |
| Gupta, CM | 1 |
| Bhate, RD | 1 |
| Bhate, RP | 1 |
| Baohang, J | 1 |
| Noordeen, SK | 1 |
| Chatterjee, BR | 2 |
| Yu, XL | 1 |
| Zhang, MS | 1 |
| Duan, CX | 1 |
| Huang, WB | 1 |
| Zhang, SB | 1 |
| Zhu, K | 1 |
| Ma, JF | 1 |
| Pavithran, K | 1 |
| Garraud, O | 1 |
| Ribierre, O | 1 |
| Bach, MA | 2 |
| Li, WZ | 1 |
| Sehgal, VN | 1 |
| Sharma, V | 1 |
| Rao, CK | 1 |
| Mittal, BN | 1 |
| Dharmshaktu, NS | 1 |
| Tiwari, VD | 1 |
| Tutakne, MA | 1 |
| Singh, G | 1 |
| Bourée, P | 1 |
| Carré, N | 1 |
| Drahmane, S | 1 |
| Ramakrishnan, KR | 1 |
| Arora, PN | 1 |
| Aggarwal, SK | 1 |
| Ramachandra, S | 1 |
| Baohong, J | 1 |
| Matsuo, Y | 1 |
| Colston, MJ | 1 |
| Pieters, FA | 1 |
| Woonink, F | 1 |
| Zuidema, J | 1 |
| Ye, GY | 1 |
| Bhatia, VN | 2 |
| Floch, HA | 1 |
| Hoffenbach, A | 1 |
| Harikrishnan, S | 1 |
| Davy, C | 1 |
| Riveau, E | 1 |
| Bousquet, JC | 1 |
| Curet, P | 1 |
| Vayre, P | 1 |
| Cortez, A | 1 |
| Grellet, J | 1 |
| Bahmer, FA | 1 |
| Menzel, S | 1 |
| Onsun, N | 1 |
| Martinez Cruz, D | 1 |
| Mehta, J | 1 |
| Gandhi, IS | 1 |
| Sane, SB | 1 |
| Wamburkar, MN | 1 |
| Andrade, VL | 1 |
| Marques, AB | 1 |
| da Cunha, LH | 1 |
| Avelleira, JR | 1 |
| Kayembe, T | 1 |
| Nollet, E | 1 |
| Coussens, L | 1 |
| Rathi, SS | 1 |
| Chaturvedi, VN | 1 |
| Raizada, RM | 1 |
| Jain, SK | 1 |
| van Asbeck-Raat, AM | 1 |
| Hassan, M | 1 |
| Chaumet, S | 1 |
| Brauner, M | 1 |
| Labadie, H | 1 |
| Mathur, A | 1 |
| Girdhar, BK | 1 |
| Ffytche, TJ | 1 |
| Ji, BH | 1 |
| Parikh, DA | 1 |
| Maniar, JK | 1 |
| Parikh, AC | 1 |
| Rook, GA | 1 |
| Samuel, NM | 1 |
| Samual, S | 1 |
| Fairbairn, T | 1 |
| Adiga, RB | 1 |
| Gammon, PT | 1 |
| Mansfield, RE | 1 |
| Lim, SD | 1 |
| Kiszkiss, DF | 1 |
| Choi, YS | 1 |
| Good, RA | 1 |
| Rosenfeld, M | 1 |
| Shepard, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters[NCT00265226] | Phase 3 | 1,020 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters[NCT00341328] | Phase 3 | 300 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients[NCT00669643] | Phase 4 | 859 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
38 reviews available for clofazimine and Leprosy
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Leprosy, Multi | 2023 |
Metabolism and interactions of antileprosy drugs.
Topics: Acedapsone; Biological Availability; Biotransformation; Clofazimine; Cytochrome P-450 CYP3A; Dapsone | 2020 |
Clofazimine: an old drug for never-ending diseases.
Topics: Animals; Anti-Bacterial Agents; Clofazimine; Drug Resistance, Bacterial; Humans; Leprosy; Mycobacter | 2020 |
Treatment of histoid leprosy: a lack of consensus.
Topics: Clofazimine; Consensus; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy | 2020 |
Multidrug therapy for leprosy: a game changer on the path to elimination.
Topics: Clofazimine; Dapsone; Disease Eradication; Drug Therapy, Combination; Humans; Leprostatic Agents; Le | 2017 |
Leprosy – an old infectious disease with unsolved matters.
Topics: Animals; Armadillos; Clofazimine; Cross-Sectional Studies; Dapsone; Disease Reservoirs; Drug Therapy | 2016 |
Update on the epidemiology, diagnosis, and treatment of leprosy.
Topics: Antibodies, Bacterial; Bacteriological Techniques; Biopsy; Clofazimine; Dapsone; Drug Resistance, Ba | 2015 |
Arthritis in leprosy.
Topics: Arthritis; Clofazimine; Dapsone; Diagnosis, Differential; Humans; Leprostatic Agents; Leprosy; Mycob | 2010 |
Clofazimine: current status and future prospects.
Topics: Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; | 2012 |
Leprosy.
Topics: Bacterial Vaccines; BCG Vaccine; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; M | 2002 |
THE ANTIMYCOBACTERIAL ACTIVITY OF B 663.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Clofazimine; Cricetinae; Drug Resistance; Dru | 1965 |
A overview of ocular leprosy after 2 decades of multidrug therapy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Eye Infections, Bacterial; Global Health; Humans; L | 2007 |
[Hansen's disease: case report and review of literature].
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Male; Middle A | 2008 |
The chemotherapy of leprosy.
Topics: Animals; Clofazimine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Kinetics; Lep | 1983 |
Evolution of the modern chemotherapy of leprosy.
Topics: Animals; Clofazimine; Dapsone; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance, Micro | 1983 |
Recent changes in leprosy control.
Topics: Bacterial Vaccines; Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium | 1983 |
The immunopharmacology of antileprosy agents.
Topics: Antigens, Bacterial; Clofazimine; Dapsone; Erythema Nodosum; Humans; Immune Tolerance; Immunity, Cel | 1983 |
Leprosy (Hansen's disease).
Topics: Clofazimine; Dapsone; Ear Deformities, Acquired; Humans; Leprosy; Mouth Diseases; Nose Deformities, | 1982 |
[Leprosy--current aspects of a disease from biblical times].
Topics: Bible; Clofazimine; Glucocorticoids; History, Ancient; Humans; Immunotherapy; Leprostatic Agents; Le | 1995 |
The pharmacology, metabolism, and chemistry of clofazimine.
Topics: Absorption; Animals; Biological Availability; Chromatography, High Pressure Liquid; Clofazimine; Hal | 1995 |
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A | 1996 |
[Chemotherapy of Hansen's disease in Japan--present status].
Topics: Anti-Infective Agents; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Humans; | 1998 |
Update on leprosy.
Topics: Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Leprostatic Agents | 2001 |
Leprosy.
Topics: Clofazimine; Cost-Benefit Analysis; Dapsone; Drug Therapy, Combination; Global Health; Humans; Inter | 2001 |
Leprosy. Recognition and treatment.
Topics: Adolescent; Adult; Age Factors; Biopsy; Child; Clinical Trials as Topic; Clofazimine; Dapsone; Diagn | 2001 |
Leprosy reactional states and their treatment.
Topics: Antigen-Antibody Complex; Clofazimine; Dapsone; Humans; Immunity, Cellular; Leprosy; Prednisolone; T | 1977 |
Lamprene (clofazimine) in leprosy. Basic information.
Topics: Chemical Phenomena; Chemistry; Clofazimine; Humans; Leprosy | 1979 |
Chemotherapy in Leprosy.
Topics: Acetamides; Anemia, Hemolytic; Aniline Compounds; Animals; Clofazimine; Dapsone; Disease Models, Ani | 1975 |
[Leprosy therapy and pharmacogenetics (author's transl)].
Topics: Acetyltransferases; Clofazimine; Cytochrome-B(5) Reductase; Dapsone; Glucosephosphate Dehydrogenase; | 1975 |
Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine.
Topics: Clofazimine; Humans; Leprosy; Mycobacterium Infections | 1992 |
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational proced
Topics: Clofazimine; Dapsone; Epidemiologic Methods; Ethiopia; Humans; Incidence; Leprostatic Agents; Lepros | 1992 |
Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection.
Topics: Acquired Immunodeficiency Syndrome; Clofazimine; Drug Interactions; Gastrointestinal Diseases; Human | 1991 |
Chemotherapy of leprosy.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leprosy; Rifa | 1988 |
Screening of drugs for activity against Mycobacterium leprae.
Topics: Animals; Clofazimine; Dapsone; Drug Evaluation, Preclinical; Leprostatic Agents; Leprosy; Mice; Myco | 1987 |
Drug resistance in leprosy--a review.
Topics: Animals; Clofazimine; Dapsone; Drug Resistance, Microbial; Ethionamide; Humans; Leprosy; Mice; Micro | 1985 |
Growing points in leprosy research. 4. Recent advances in the chemotherapy of leprosy.
Topics: Clofazimine; Dapsone; Ethionamide; Humans; Leprosy; Rifampin; Sulfonamides; Thioacetazone; Thiourea | 1974 |
The first decade in experimental leprosy.
Topics: Animals; BCG Vaccine; Clofazimine; Dapsone; Disease Models, Animal; Drug Evaluation; Drug Evaluation | 1971 |
41 trials available for clofazimine and Leprosy
| Article | Year |
|---|---|
Comparative efficacy of four treatment regimens in Type 2 Leprosy Reactions (Prednisolone alone, Thalidomide alone, Prednisolone plus Thalidomide and Prednisolone plus Clofazimine).
Topics: Adult; Clofazimine; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Longitud | 2016 |
Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Topics: Adolescent; Adult; Anemia; Brazil; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Female; H | 2018 |
Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: a double-blind, randomized, controlled study.
Topics: Adult; Arthritis, Reactive; Clofazimine; Double-Blind Method; Female; Humans; Inflammation; Leprosta | 2015 |
Plasma levels of chemokines during leprosy specific treatment.
Topics: Adult; Aged; Chemokine CCL11; Chemokine CCL24; Chemokines; Clofazimine; Dapsone; Drug Therapy, Combi | 2010 |
Biochemical and hematological side effects of clofazimine in leprosy patients.
Topics: Blood Cell Count; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agent | 2002 |
Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agen | 2004 |
International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results.
Topics: Adolescent; Adult; Aged; Child; China; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Huma | 2008 |
Treatment of sulphone resistant leprosy--a review of sixty one cases.
Topics: Adult; Clinical Trials as Topic; Clofazimine; Drug Resistance, Microbial; Female; Humans; Leprostati | 1982 |
Clofazimine in lepra (ENL) reaction, one year clinical trial.
Topics: Adult; Clinical Trials as Topic; Clofazimine; Erythema Nodosum; Female; Humans; Leprosy; Male; Middl | 1983 |
THELEP controlled clinical trials in lepromatous leprosy.
Topics: Animals; Clinical Trials as Topic; Clofazimine; Dapsone; Female; Humans; Leprostatic Agents; Leprosy | 1983 |
[Field experiences with therapy protocols in leprosy].
Topics: Clinical Trials as Topic; Clofazimine; Dapsone; Drug Administration Schedule; Humans; Leprostatic Ag | 1983 |
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Clofazim | 1984 |
Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report.
Topics: Acedapsone; Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Clofazimine; | 1984 |
Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy.
Topics: Candida albicans; Cell Movement; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; L | 1982 |
Vitamin A levels of ichthyotic and non-ichthyotic skin and plasma of leprosy patients with and without clofazimine therapy.
Topics: Clofazimine; Humans; Ichthyosis; Leprosy; Skin; Vitamin A | 1982 |
Long-term evaluation of immune status in leprosy patients undergoing multiple drug therapy.
Topics: Agglutination Tests; Antibodies, Bacterial; Antigens, Bacterial; Clofazimine; Dapsone; Drug Therapy, | 1994 |
A randomized clinical trial of two single-dose treatments for paucibacillary leprosy.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clofazimine; Dapsone; Drug Administration Schedule | 1994 |
Reversal reaction in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w.
Topics: Bacterial Vaccines; Clofazimine; Combined Modality Therapy; Dapsone; Drug Therapy, Combination; Huma | 1993 |
Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
Topics: Blood Cell Count; Blood Chemical Analysis; Clofazimine; Dapsone; Drug Therapy, Combination; Female; | 1997 |
Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy.
Topics: Adrenal Cortex Hormones; Clofazimine; Cytokines; Drug Therapy, Combination; Female; Follow-Up Studie | 1998 |
Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy.
Topics: Adolescent; Adult; Antibodies, Bacterial; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Fe | 1999 |
Effect of zafirlukast on leprosy reactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clofazimine; Cohort Studies; D | 1999 |
Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Glucosephosphate Dehydro | 1999 |
Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antilepro
Topics: Bacterial Vaccines; Clofazimine; Dapsone; Double-Blind Method; Drug Therapy, Combination; Humans; Im | 1999 |
Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antilepro
Topics: Bacterial Vaccines; Clofazimine; Dapsone; Double-Blind Method; Drug Therapy, Combination; Humans; Im | 1999 |
Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antilepro
Topics: Bacterial Vaccines; Clofazimine; Dapsone; Double-Blind Method; Drug Therapy, Combination; Humans; Im | 1999 |
Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antilepro
Topics: Bacterial Vaccines; Clofazimine; Dapsone; Double-Blind Method; Drug Therapy, Combination; Humans; Im | 1999 |
A 6 week quadruple drug regimen for the treatment of multibacillary leprosy.
Topics: Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 2000 |
Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Topics: Adult; Clofazimine; Cohort Studies; Dapsone; Drug Therapy, Combination; Female; Follow-Up Studies; H | 2000 |
A statistical analysis of two chemotherapy trials in lepromatous leprosy. I. The response to therapy as measured by inoculation of mice.
Topics: Adolescent; Adult; Aged; Animals; Clinical Trials as Topic; Clofazimine; Dapsone; Female; Humans; Le | 1978 |
A statistical analysis of two chemotherapy trials in lepromatous leprosy. II. Interactions among patient variables.
Topics: Adolescent; Adult; Age Factors; Aged; Cell Count; Clinical Trials as Topic; Clofazimine; Dapsone; Fe | 1978 |
Evaluation of treatment of lepromatous leprosy patients in the Netherlands.
Topics: Clinical Trials as Topic; Clofazimine; Dapsone; Drug Evaluation; Humans; Leprostatic Agents; Leprosy | 1979 |
Spaced clofazimine therapy of lepromatous leprosy.
Topics: Adolescent; Adult; Aged; Biopsy; Clofazimine; Dapsone; Drug Evaluation; Female; Humans; Leprosy; Mal | 1976 |
Long-term follow-up of clofazimine (Lamprene) in the management of reactive phases of leprosy.
Topics: Clinical Trials as Topic; Clofazimine; Dapsone; Female; Follow-Up Studies; Humans; Leprosy; Pregnanc | 1975 |
The effect of long-term steroid therapy on patients treated with clofazimine (Lamprene).
Topics: Clinical Trials as Topic; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Huma | 1975 |
Open trial with clofazimine in the management of recurrent lepra reaction and of sulphone sensitive cases: a preliminary report.
Topics: Adult; Clinical Trials as Topic; Clofazimine; Drug Hypersensitivity; Humans; Leprosy; Male; Sulfones | 1975 |
A controlled clinical trial of continuous and intermittent rifampicin therapy during an initial three months period in lepromatous leprosy: final analysis.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Clofazimine; Dapsone; Female; Humans; Leprosy; Ma | 1975 |
Combined therapy in leprosy.
Topics: Adult; Clinical Trials as Topic; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostati | 1975 |
Personal experience with clofazimine in the treatment of leprosy.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Clofazimine; Female; Humans; Leprosy; Male; Middl | 1975 |
Treatment of multibacillary leprosy with a regimen of 13 weeks duration.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Ethionamide; Humans; Leprostatic Agents; Leprosy; P | 1992 |
Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report.
Topics: Adolescent; Adult; Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Isoniaz | 1988 |
Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
Topics: Clinical Trials as Topic; Clofazimine; Cohort Studies; Dapsone; Drug Administration Schedule; Ethion | 1989 |
Combined regimens of one year duration in the treatment of multibacillary leprosy--II. Combined regimens with rifampicin administered during 6 months.
Topics: Clinical Trials as Topic; Clofazimine; Cohort Studies; Dapsone; Drug Administration Schedule; Ethion | 1989 |
Efficacy of different regimens in multibacillary leprosy.
Topics: Clinical Trials as Topic; Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combinat | 1986 |
242 other studies available for clofazimine and Leprosy
| Article | Year |
|---|---|
Interaction of constituents of MDT regimen for leprosy with Mycobacterium leprae HSP18: impact on its structure and function.
Topics: Antigens, Bacterial; Bacterial Proteins; Clofazimine; Dapsone; Heat-Shock Proteins; Host-Pathogen In | 2022 |
Clofazimine induced pigmentation in leprosy patches.
Topics: Clofazimine; Humans; Leprosy; Pigmentation; Pigmentation Disorders | 2022 |
Extemporaneously compounded liquid formulations of clofazimine.
Topics: Child; Clofazimine; Drug Compounding; Humans; Leprosy; Pharmaceutical Services; Tuberculosis | 2023 |
4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.
Topics: Alzheimer Disease; Clofazimine; Cognitive Dysfunction; Coronavirus Infections; COVID-19; Dapsone; Hu | 2020 |
Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
Topics: Adolescent; Adult; Alleles; Biomarkers; Case-Control Studies; Clofazimine; Dapsone; Drug Hypersensit | 2020 |
Analysis of bacteriological Index between fixed multidrug therapy and new WHO recommended alternative regimen with ofloxacin, minocycline and clofazimine of rifampicin resistant cases from the hospitals of The Leprosy Mission, India.
Topics: Clofazimine; Drug Therapy, Combination; Hospitals; Humans; India; Leprostatic Agents; Leprosy; Minoc | 2020 |
Endemic leprosy, scarcity of clofazimine in pharmacies, and the ensuing therapeutic void.
Topics: Clofazimine; Humans; Leprosy; Pharmacies | 2021 |
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study.
Topics: Adrenal Cortex Hormones; BCG Vaccine; Brazil; Clofazimine; Cohort Studies; COVID-19; COVID-19 Drug T | 2021 |
Painless Nodular Rash in a Young Man.
Topics: Adult; Clofazimine; Dapsone; Diagnosis, Differential; Exanthema; Humans; Leprostatic Agents; Leprosy | 2017 |
Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clofazimine; Cross-Over Studies; Drug Therapy, Co | 2017 |
A Traditional NSAID Aspirin along with Clofazimine in Erythema Nodosum Leprosum Reaction: Study of Six Cases.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clofazimine; Dapsone; Drug Therapy, Combina | 2016 |
Dapsone Resistance in Leprosy Patients Originally from American Samoa, United States, 2010-2012.
Topics: American Samoa; Biopsy; Clofazimine; Dapsone; Drug Administration Schedule; Drug Resistance, Bacteri | 2018 |
Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Topics: Adult; Alleles; China; Clofazimine; Cohort Studies; Dapsone; Drug Hypersensitivity Syndrome; Drug Th | 2019 |
Image Gallery: Clofazimine-induced hyperpigmentation of leprosy plaques.
Topics: Clofazimine; Drug Therapy, Combination; Face; Humans; Hyperpigmentation; Leprosy; Male; Skin | 2019 |
Clofazimine should be used in all cases of leprosy, says Indian research council.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Humans; India; Leprostatic Agents; Leprosy | 2013 |
An under-recognized cause of polyarthritis: leprosy.
Topics: Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Clofazimine; Dapsone; Delayed Diagnosis; | 2013 |
Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
Topics: Adult; Analysis of Variance; Catalase; Clofazimine; Cytochrome P-450 CYP2C19; Dapsone; Drug Therapy, | 2014 |
Leprosy.
Topics: Aged, 80 and over; Clofazimine; Dapsone; Humans; Leprostatic Agents; Leprosy; Male; Mycobacterium le | 2014 |
Leprosy in the UK.
Topics: Clofazimine; Dapsone; Humans; Leprostatic Agents; Leprosy; Peripheral Nervous System Diseases; Rifam | 2016 |
Hansen's disease in Portugal: multibacillary patients treated between 1988 and 2003.
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Lepros | 2009 |
[Sensory-motor neuropathy: a slow and misleading case of leprosy].
Topics: Adrenal Cortex Hormones; Aged; Aspirin; Clofazimine; Dapsone; Diagnosis, Differential; Female; Human | 2008 |
A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Topics: Adolescent; Adult; Aged; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostati | 2008 |
Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
Topics: Adult; Agranulocytosis; Anemia, Hemolytic; Clofazimine; Dapsone; Drug Therapy, Combination; Female; | 2009 |
Lest we forget Hansen's disease (leprosy): an unusual presentation with an acute onset of inflammatory polyarthritis and the rheumatology experience.
Topics: Acute Disease; Aged; Arthritis; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Combina | 2009 |
Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Hyperpigmentation; Leprostatic Agents; Lepr | 2010 |
Interferon-gamma receptor-1 gene promoter polymorphisms and susceptibility to leprosy in children of a single family.
Topics: Child; Clofazimine; Family; Genetic Predisposition to Disease; Humans; Interferon gamma Receptor; Le | 2011 |
Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Topics: Adolescent; Adult; Body Mass Index; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; | 2011 |
Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy.
Topics: Animals; Bacterial Proteins; Biopsy; Clofazimine; Cross-Sectional Studies; Dapsone; Dihydropteroate | 2011 |
Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Biopsy; Clofazimine; Dapsone; Drug Adm | 2011 |
Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leprostatic A | 2012 |
Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Brazil; Clofazimine; Dapsone; Drug Therapy, Combination; | 2012 |
Drug susceptibility of Mycobacterium leprae: a retrospective analysis of mouse footpad inoculation results from 1983 to 1997.
Topics: Adult; Animals; Clofazimine; Dapsone; Drug Resistance, Multiple, Bacterial; Female; Humans; India; L | 2002 |
Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
Topics: Belgium; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hu | 2002 |
Short report: Treatment failure in Hansen's disease.
Topics: Adolescent; Adult; Aged; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Lep | 2003 |
Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Topics: Acedapsone; Adult; Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Fe | 2003 |
"B 663" in the treatment of leprosy. Supplementary report of the pilot trial.
Topics: Clofazimine; Heterocyclic Compounds; Leprosy | 1962 |
Apparent resistance of M. leprae to "B 663".
Topics: Clofazimine; Heterocyclic Compounds; Leprosy; Mycobacterium leprae | 1962 |
"B 663" in the treatment of leprosy. Preliminary report of a pilot trial.
Topics: Clofazimine; Heterocyclic Compounds; Leprosy | 1962 |
TREATMENT OF LEPROSY WITH B 663 APPRAISAL OF THE PILOT TRIAL AFTER THREE YEARS.
Topics: Antitubercular Agents; Biomedical Research; Black People; Clofazimine; Drug Therapy; Humans; Leprosy | 1965 |
RED AND BLACK PIGMENTATION DEVELOPING DURING TREATMENT OF LEPROSY WITH 'B 663'.
Topics: Antitubercular Agents; Black People; Clofazimine; Drug Therapy; Humans; Leprosy; Pathology; Phenazin | 1965 |
'B 663' POSSIBLE ANTI-INFLAMMATORY ACTION IN LEPROMATOUS LEPROSY.
Topics: Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Drug Resistance; Drug Resistance, Micr | 1965 |
Determination of clofazimine in leprosy patients by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Clofazimine; Drug Monitoring; Female; Humans; Leprostatic Agen | 2003 |
Shiny red-brown papules in a 21-year-old man. Histoid leprosy.
Topics: Adult; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Face; Humans; Lepro | 2004 |
DNA damage studies in untreated and treated leprosy patients.
Topics: Adolescent; Adult; Aged; Clofazimine; Dapsone; DNA Damage; Female; Humans; Leprostatic Agents; Lepro | 2004 |
[Clofazimine. Current status of therapy with clofazimine (Lampren) for leprosy, erythema leprosum , and other dermatoses after donation of the medicine to the WHO by Novartis].
Topics: Charities; Clinical Trials as Topic; Clofazimine; Erythema Nodosum; Germany; Humans; Leprosy; Skin D | 2005 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Chemotherapy of leprosy.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; Dr | 2004 |
Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Topics: Acute Kidney Injury; Adult; Clofazimine; Dapsone; Drug Hypersensitivity; Drug Therapy, Combination; | 2005 |
Remitting seronegative symmetrical synovitis with pitting edema in leprosy.
Topics: Aged; Clofazimine; Dapsone; Drug Therapy, Combination; Edema; Foot; Humans; Leprostatic Agents; Lepr | 2006 |
Renal hypersensitivity vasculitis associated with dapsone.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Clofazimine; Cyclophosphamide; Dapsone; Drug Hy | 2005 |
[Dermopathy and peripheral neuropathy].
Topics: Aged; Clofazimine; Dapsone; Exanthema; Humans; Hypesthesia; Leprostatic Agents; Leprosy; Male; Rifam | 2005 |
Epidemiology of leprosy and response to treatment in Hong Kong.
Topics: Clofazimine; Dapsone; Drug Resistance, Bacterial; Drug Therapy, Combination; Hong Kong; Humans; Inci | 2006 |
[Guideline for the treatment of Hansen's disease in Japan (Second edition)].
Topics: Clofazimine; Congenital Abnormalities; Dapsone; Drug Resistance, Microbial; Drug Therapy, Combinatio | 2006 |
[Basic evaluation for new antimicrobial susceptibility testing of Mycobacterium leprae by bioluminescence assay (ATP method)].
Topics: Animals; Clarithromycin; Clofazimine; Drug Resistance, Bacterial; Leprostatic Agents; Leprosy; Lucif | 2006 |
Multidrug therapy regimen for leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Practice Guide | 2006 |
An unusual rash in an elderly man.
Topics: Age Factors; Aged, 80 and over; Clofazimine; Dapsone; Diagnosis, Differential; Exanthema; Humans; Le | 2007 |
Multidrug therapy in leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Rifampin; Worl | 2006 |
Photosensitisation induced by clofazimine in a cat.
Topics: Animals; Cat Diseases; Cats; Clofazimine; Female; Leprostatic Agents; Leprosy; Photosensitivity Diso | 2007 |
[Long-term follow-up of ofloxacin-combined therapy for leprosy patients].
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Cystamine; Drug Therapy, Combination; Follow-Up Studies; H | 2007 |
Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Topics: Adult; Brazil; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; | 2007 |
Three indigenous cases of leprosy in the Mississippi delta.
Topics: Aged; Aged, 80 and over; Animals; Armadillos; Biopsy; Clofazimine; Dapsone; Diagnosis, Differential; | 2008 |
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine.
Topics: Adult; Clofazimine; Edetic Acid; Female; Ferrous Compounds; Free Radicals; Humans; Hydroxides; Hydro | 1984 |
Evaluation of multiple regimens in leprosy.
Topics: Clofazimine; Dapsone; Drug Evaluation; Drug Therapy, Combination; Humans; Leprosy; Male; Rifampin; S | 1981 |
Multiple drug therapy--a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH and thiacetazone in lepromatous cases.
Topics: Adolescent; Adult; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Isoniazid | 1981 |
Evaluation of drug regimen in lepromatous leprosy--II.
Topics: Adult; Animals; Clofazimine; Dapsone; Drug Administration Schedule; Drug Resistance, Microbial; Huma | 1983 |
Side-effects of antileprosy drugs in common use.
Topics: Clofazimine; Dapsone; Drug Hypersensitivity; Ethionamide; Humans; Leprostatic Agents; Leprosy; Rifam | 1983 |
Intra-neural ceroid-like pigment following the treatment of lepromatous leprosy with clofazimine (B663; Lamprene).
Topics: Adult; Ceroid; Clofazimine; Dapsone; Drug Therapy, Combination; Histocytochemistry; Humans; Leprosy; | 1981 |
The treatment of leprosy.
Topics: Adult; Animals; Clofazimine; Dapsone; Drug Resistance, Microbial; Erythema Nodosum; Ethionamide; Hum | 1983 |
How much non-infectious are the "non-infectious" lepromatous leprosy patients?
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Mycobacterium leprae; Nose; Rifamp | 1983 |
Leprosy today.
Topics: Clofazimine; Dapsone; Disease Models, Animal; Drug Resistance, Microbial; Humans; Leprosy; Mycobacte | 1983 |
Successful plasma exchange in type 1 leprosy reversal reaction.
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Leukocyte Count; Male; Plas | 1984 |
Clofazimine and the eye: preliminary communication.
Topics: Adolescent; Adult; Clofazimine; Eye; Female; Humans; Leprosy; Male; Middle Aged; Pigmentation | 1984 |
Treatment of leprosy in rural India as seen on a medical student elective.
Topics: Clofazimine; Dapsone; Developing Countries; Drug Therapy, Combination; Humans; India; Leprosy; Patie | 1984 |
[Features of the clinical picture and treatment of leprosy in Vietnam].
Topics: Clofazimine; Female; Humans; Leprostatic Agents; Leprosy; Male; Rifampin; Vietnam | 1983 |
[Effects of antileprotic agents (clofazimine) on the phagocytosis of leprotic patients and possible etiological explanation of Hansen's disease].
Topics: Adult; Clofazimine; Female; Humans; Leprosy; Male; Middle Aged; Phagocytosis | 1983 |
New approaches to chemotherapy for leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Rifampin | 1983 |
Field application of combined therapy for infectious leprosy cases. A feasibility study in Bombay.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Evaluation; Drug Therapy, Combination; Humans; India; | 1983 |
Oral zinc in recurrent Erythema Nodosum Leprosum reaction.
Topics: Administration, Oral; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Erythema Nodosum; Fema | 1983 |
The effect of clofazimine on liver function tests in lepra reaction (ENL).
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Blood Proteins; | 1983 |
The effect of clofazimine on the plaque-forming cell response.
Topics: Animals; Antibody Formation; Clofazimine; Erythrocytes; Female; Immunity, Cellular; Leprosy; Mice; M | 1983 |
A review of side-effects experienced by patients taking clofazimine.
Topics: Clofazimine; Digestive System; Eye Diseases; Humans; Leprosy; Pigmentation Disorders; Time Factors | 1983 |
Reduced estrogen excretion due to clofazimine?
Topics: Clofazimine; Estrogens; Female; Humans; Leprosy; Pregnancy | 1983 |
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide.
Topics: Clofazimine; Dapsone; Drug Packaging; Ethionamide; Humans; Leprostatic Agents; Leprosy; Prothionamid | 1983 |
Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction.
Topics: Autonomic Nervous System; Blood Pressure; Clofazimine; Erythema Nodosum; Histamine; Humans; Leprosy; | 1983 |
Clofazimine-resistant leprosy, a case report.
Topics: Animals; Clofazimine; Drug Resistance, Microbial; Humans; Leprosy; Male; Mice; Microbial Sensitivity | 1982 |
Leprosy and its chemotherapy.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium leprae; Rifampin | 1982 |
Chemotherapy of leprosy for control programmes: scientific basis and practical application.
Topics: Clofazimine; Costs and Cost Analysis; Dapsone; Drug Resistance, Microbial; Humans; Leprostatic Agent | 1983 |
Leprosy in Auckland.
Topics: Adult; Clofazimine; Dapsone; Female; Fiji; Humans; Independent State of Samoa; Leprosy; Male; New Ze | 1980 |
[Jorge Lobo disease. Study of 22 new cases].
Topics: Adult; Aged; Brazil; Clofazimine; Dermatomycoses; Electrocoagulation; Female; Humans; Leishmaniasis; | 1981 |
Leprosy.
Topics: Animals; Armadillos; Cercopithecidae; Clofazimine; Cricetinae; Disease Models, Animal; Female; Human | 1982 |
Clofazimine in pregnancy complicated by leprosy.
Topics: Adult; Clofazimine; Female; Humans; Infant, Newborn; Leprosy; Pregnancy; Pregnancy Complications, In | 1982 |
Clofazimine-induced ichthyosis and its treatment.
Topics: Clofazimine; Humans; Ichthyosis; Leprosy | 1982 |
Determination of clofazimine in plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Clofazimine; Humans; Leprosy; Reference Values | 1982 |
Progressive lepra reaction. A case report.
Topics: Adrenal Cortex Hormones; Adult; Clofazimine; Humans; Leprosy; Male | 1982 |
Possible incompatibility of dapsone with clofazimine in the treatment of patients with erythema nodosum leprosum.
Topics: Clofazimine; Dapsone; Erythema Nodosum; Female; Humans; Leprosy; Male | 1982 |
Study of toxicity of clofazimine with special reference to structural and functional status of small intestine.
Topics: Clofazimine; Digestive System; Eye; Humans; Intestinal Absorption; Jejunum; Leprosy; Skin Pigmentati | 1982 |
Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978.
Topics: Adolescent; Adult; Aged; Biopsy; Child; Clofazimine; Female; Humans; Leprosy; Male; Middle Aged; Ski | 1981 |
Rifampin 1200 mg once monthly together with daily Lamprene and dapsone in treatment of refactory patients with lepromatous leprosy.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Fe | 1981 |
Drug interactions -- the influence of rifampicin and clofazimine on the urinary excretion of DDS.
Topics: Clofazimine; Creatinine; Dapsone; Drug Interactions; Humans; Leprosy; Rifampin | 1981 |
Leprosy in an albino.
Topics: Adult; Albinism; Clofazimine; Humans; Leprosy; Male | 1981 |
Clofazimine (lamprene or B663) in lepra reactions.
Topics: Adult; Clofazimine; Dapsone; Female; Humans; Leprosy; Prednisolone | 1981 |
A study of cell mediated immunity in leprosy.
Topics: Adolescent; Adult; Child; Clofazimine; Dapsone; Female; Humans; Immunity, Cellular; Leprostatic Agen | 1981 |
Multi-drug treatment for reactions in leprosy.
Topics: Adolescent; Adult; Child; Chloroquine; Clofazimine; Diethylcarbamazine; Drug Therapy, Combination; F | 1981 |
Gastro-intestinal side effects of clofazimine.
Topics: Adult; Clofazimine; Female; Gastrointestinal Diseases; Humans; Leprosy; Male | 1981 |
[Chemotherapy of leprosy. II. Sulfones and sulfonamides].
Topics: Clofazimine; Drug Resistance, Microbial; Ethionamide; Humans; Leprostatic Agents; Leprosy; Prothiona | 1980 |
Study on drug interactions.
Topics: Adult; Clofazimine; Dapsone; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Lepros | 1980 |
Clofazimine and dapsone--a combination therapy in erythema nodosum leprosum syndrome.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Erythema Nodosum; Female; Humans | 1980 |
Does clofazimine have any value in the management of reversal reaction?
Topics: Clofazimine; Humans; Leprosy | 1980 |
Leprosy.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Resistance, Microbial; Humans; Leprostatic | 1995 |
Treating Hansen's disease in developing countries.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Rifampin | 1994 |
Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients.
Topics: Adolescent; Adult; Aged; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Electrophysiology; | 1993 |
Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.
Topics: Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Leprostatic Agents; Leprosy; Mice; Mice, I | 1994 |
Activity of phenazine analogs against Mycobacterium leprae infections in mice.
Topics: Abdomen; Adipose Tissue; Animals; Clofazimine; Disease Models, Animal; Drug Evaluation, Preclinical; | 1993 |
Therapeutic monitoring and pharmacist intervention in a Hansen's disease clinic.
Topics: Academic Medical Centers; Chicago; Clofazimine; Dapsone; Drug Monitoring; Humans; Leprosy; Patient C | 1993 |
Severe abdominal pain in low dosage clofazimine.
Topics: Abdominal Pain; Adult; Clofazimine; Humans; Leprosy; Lymph Nodes; Male | 1993 |
Problems of leprosy relapse in China.
Topics: China; Clofazimine; Dapsone; Drug Therapy, Combination; Follow-Up Studies; Humans; Leprosy; Recurren | 1993 |
Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Topics: Adult; Aged; Aged, 80 and over; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Lep | 1993 |
Urinary excretion of renal brush border membrane enzymes in leprosy patients--effect of multidrug therapy.
Topics: Alkaline Phosphatase; Biomarkers; Clofazimine; Dapsone; Drug Monitoring; Drug Therapy, Combination; | 1996 |
Antileprosy drugs, pregnancy and fetal outcome.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Animals; Clofazimine; Dapsone; Drug Therapy, Combina | 1996 |
Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Male; | 1997 |
Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic
Topics: Adoptive Transfer; Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Granulocyte-Mac | 1997 |
[New WHO recommendations for the treatment of leprosy].
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocycline; M | 1997 |
Leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Rifampin | 1997 |
Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combin | 1998 |
Serum markers of treatment success in leprosy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers; Child; Clofazimine; Dapsone; Dr | 1999 |
Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bacterial Vaccines; Clofazimine; Disabled Persons; Double-B | 1999 |
Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bacterial Vaccines; Clofazimine; Disabled Persons; Double-B | 1999 |
Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bacterial Vaccines; Clofazimine; Disabled Persons; Double-B | 1999 |
Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bacterial Vaccines; Clofazimine; Disabled Persons; Double-B | 1999 |
Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
Topics: Adult; Animals; Biological Assay; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Histocyto | 1999 |
Single-dose treatment for paucibacillary leprosy; clinical problems and management.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clofazimine; Drug Therapy, Combinat | 1999 |
Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient.
Topics: Abdominal Pain; Adult; Biopsy; Chronic Disease; Clofazimine; Crystallization; Cytoplasm; Diagnosis, | 2000 |
Ominous sign of a disfiguring disease. Leprosy (Hansen's disease).
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Leprosy | 2000 |
Clofazimine: new products. Major antileprous drug.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Rifampin; Trea | 1999 |
Viewpoint: leprosy after the year 2000.
Topics: Clofazimine; Drug Therapy, Combination; Global Health; Humans; Hypersensitivity, Delayed; Leprostati | 2000 |
Effect of treatment on PCR positivity in multibacillary leprosy patients treated with conventional and newer drugs ofloxacin and minocycline.
Topics: Adenosine Triphosphate; Biopsy; Clofazimine; Dapsone; DNA, Bacterial; Drug Evaluation; Drug Therapy, | 1999 |
Dapsone drug resistance in the MDT era.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Leprostatic Age | 2000 |
Hansen's disease in a native-born, United States resident, after a brief stay in an endemic area abroad.
Topics: Aged; Cell Count; China; Clofazimine; Dapsone; Diabetes Mellitus, Type 1; Emigration and Immigration | 2001 |
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Colony Count, Mi | 2000 |
Treatment of Hansen's disease.
Topics: Clofazimine; Dapsone; Dermatomycoses; Diagnosis, Differential; Drug Therapy, Combination; Humans; Le | 2002 |
Letter: Ocular side-effects of clofazimine.
Topics: Clofazimine; Cornea; Eye; Humans; Leprosy; Retina | 1975 |
[Leprosy and the nervous system (author's transl)].
Topics: Adult; Antibody Formation; Central Nervous System Diseases; Clofazimine; Dapsone; Diagnosis, Differe | 1979 |
Management of sulphone-resistant lepromatous leprosy.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium leprae; Thalidomide | 1977 |
The diagnosis and management of dapsone-resistant leprosy.
Topics: Clofazimine; Dapsone; Diagnosis, Differential; Drug Resistance, Microbial; Humans; Leprosy; Mycobact | 1977 |
Committee 4: workshop on experimental chemotherapy of leprosy.
Topics: Animals; Antitubercular Agents; Clofazimine; Dapsone; Drug Resistance, Microbial; Leprostatic Agents | 1979 |
The treatment of leprosy today and tomorrow: the LEPRA consultation on chemotherapy.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium leprae; Patient Com | 1977 |
Workshop on "chemotherapy of leprosy" at the Central Leprosy Teaching and Research Institute, Chengalpattu (Tamil Nadu) on 21 January 1978.
Topics: Clofazimine; Dapsone; Humans; India; Leprosy; Recurrence; Rifampin; Thalidomide | 1979 |
Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine.
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Male; Recurrence; Steroids; | 1979 |
Unnecessary laparotomy for abdominal pain and fever due to clofazimine.
Topics: Abdomen; Adult; Clofazimine; Fever; Humans; Leprosy; Male; Pain | 1979 |
Leprosy and the rheumatoid factor.
Topics: Clofazimine; Dapsone; Humans; Leprosy; Rheumatoid Factor | 1978 |
Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection.
Topics: Animals; Antibodies, Bacterial; Clofazimine; Immunosuppression Therapy; Leprosy; Mice; Mycobacterium | 1976 |
Studies of experimental chemotherapy of leprosy.
Topics: Animals; Clofazimine; Leprosy; Mice; Mycobacterium leprae; Phenazines | 1976 |
Clofazimine in the treatment of dapsone resistant leprosy.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium leprae | 1976 |
Clofazimine and eosinophilic enteritis.
Topics: Adult; Clofazimine; Enteritis; Eosinophils; Female; Humans; Leprosy | 1977 |
Tissue levels of clofazimine in a case of leprosy.
Topics: Adolescent; Clofazimine; Humans; Intestinal Mucosa; Leprosy; Male; Mononuclear Phagocyte System | 1976 |
Lepromatous leprosy: dapsone resistance.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Female; Foot Deformities, Acquired; Humans; Lepros | 1976 |
The diagnosis and treatment of leprosy.
Topics: Biopsy; Clofazimine; Dapsone; Erythema Nodosum; Humans; Immunotherapy; Leprosy; Recurrence; Rifampin | 1976 |
Treatment of Hansen's disease.
Topics: Chloroquine; Clofazimine; Dapsone; Drug Resistance, Microbial; Erythema Nodosum; Humans; Leprosy; Pr | 1976 |
Transformation from lepromatous to borderline leprosy under clofazimine therapy.
Topics: Adult; Clofazimine; Dapsone; Humans; Leprosy; Male; Skin | 1976 |
The pharmacological aspects and the therapeutic effects of clofazimine.
Topics: Absorption; Animals; Clofazimine; Humans; Leprosy | 1976 |
An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug.
Topics: Adolescent; Adult; Clofazimine; Humans; Leprosy; Male; Middle Aged; Recurrence; Thalidomide | 1976 |
Experiences with clofazimine therapy in leprosy.
Topics: Adolescent; Adult; Clofazimine; Female; Humans; Leprosy; Male; Middle Aged | 1976 |
Clinical trial with clofazimine in leprosy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Child; Clofazimine; Dapsone; Drug Therapy, Combination; | 1976 |
Experiences in treatment of histoid cases with clofazimine.
Topics: Clofazimine; Dapsone; Humans; Leprosy | 1976 |
Experience with the combination of clofazimine (Lamprene) and long-term steroid therapy in the treatment of leprosy.
Topics: Clofazimine; Drug Therapy, Combination; Humans; Leprosy; Prednisolone | 1976 |
Side effects of clofazimine therapy.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Female; Humans; Ichthyosis; Isoniazid; Leprosy; Male; Skin | 1976 |
Quantitative estimation of clofazimine in tissue.
Topics: Adolescent; Autopsy; Clofazimine; Humans; Leprosy; Skin | 1976 |
Viability of Myco. leprae in the skin and bone marrow of patients with lepromatous leprosy while on dapsone or lamprene.
Topics: Bone Marrow; Clofazimine; Dapsone; Humans; Leprosy; Mycobacterium leprae; Skin | 1975 |
Treatment of leprosy with clofazimine, rifampicin and Bayrena.
Topics: Clofazimine; Drug Resistance, Microbial; Humans; Leprosy; Mycobacterium leprae; Rifampin; Sulfameter | 1975 |
Multicentre controlled comparative trial of clofazimine and dapsone in low dosages.
Topics: Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Leprosy; Mycobacter | 1975 |
Treatment of neuritis in borderline leprosy with rifampicin and corticosteroids--a pilot trial.
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy; Male; Neuritis; Pil | 1975 |
Autopsy findings in a case of lepromatous leprosy treated with clofazimine.
Topics: Adult; Autopsy; Clofazimine; Diarrhea; Female; Humans; Leprosy | 1975 |
The drug treatment of leprosy.
Topics: Acute Disease; Adrenal Cortex Hormones; Aniline Compounds; Clofazimine; Dapsone; Drug Therapy, Combi | 1975 |
Complications of treatment with clofazimine (Lamprene: B663).
Topics: Clofazimine; Gastrointestinal Diseases; Humans; Leprosy; Skin Diseases | 1976 |
A long term trial with clofazimine in reactive lepromatous leprosy.
Topics: Clofazimine; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Leprosy; Pregnancy; Time Fa | 1976 |
Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Clofazimine; Dapsone; Drug Eruptions; Dru | 1992 |
Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Ethionamide; Humans; Leprosy; Polynesia; Rifampin | 1992 |
Detection of Mycobacterium leprae and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR.
Topics: Anti-Bacterial Agents; Biopsy; Clofazimine; Dapsone; DNA Probes; DNA, Bacterial; Drug Therapy, Combi | 1992 |
Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Ethionamide; Humans; Leprostatic Agents; Leprosy | 1992 |
Comment: clofazimine-induced lymphoedema.
Topics: Adolescent; Adult; Child; Clofazimine; Female; Humans; Leprosy; Lymphedema; Male; Middle Aged | 1991 |
The response to chemotherapy of serum Mycobacterium leprae-specific antigen in multibacillary leprosy patients.
Topics: Antibodies, Bacterial; Antigens, Bacterial; Carbohydrate Sequence; Clofazimine; Dapsone; Drug Therap | 1991 |
A retrospective study on seven years of multiple drug treatment for paucibacillary and multibacillary leprosy, in Bayara General Hospital, Nigeria.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Administration Schedule; Drug Resistance, Microbial; D | 1991 |
Comment: Clofazimine-induced lymphoedema.
Topics: Clofazimine; Humans; Leprosy; Lymphedema | 1991 |
Impact of multidrug therapy on the treatment and control of leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Global Health; Humans; Leprosy; Patient Compliance; | 1991 |
Sulfapyridine and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum.
Topics: Clofazimine; Colitis, Ulcerative; Dermatitis Herpetiformis; Glycosaminoglycans; Humans; Leprosy; Pyo | 1990 |
Clofazimine-induced lymphoedema.
Topics: Adult; Clofazimine; Female; Humans; Leprosy; Lymphedema; Male; Middle Aged | 1990 |
[Late reversal reactions in leprosy].
Topics: Clofazimine; Dapsone; Drug Combinations; Ethionamide; Female; Humans; Leprosy; Male; Recurrence; Rif | 1990 |
The chemotherapy of leprosy. Part 1.
Topics: Animals; Clofazimine; Dapsone; Drug Resistance, Microbial; Drug Therapy, Combination; Ethionamide; H | 1990 |
[Drugs used in tuberculosis and leprosy].
Topics: Administration, Oral; Antibiotics, Antitubercular; Clofazimine; Dapsone; Humans; Injections, Intramu | 1990 |
Effect of three-year multidrug therapy in multibacillary leprosy patients.
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy; Leprosy, Borderline | 1990 |
Absorption and analysis of clofazimine and its derivatives.
Topics: Absorption; Animals; Clofazimine; Leprosy; Mice; Structure-Activity Relationship; Tissue Distributio | 1990 |
A study of dermatological conditions in leprosy in-patients.
Topics: Clofazimine; Drug Eruptions; Female; Humans; Inpatients; Keratosis; Leprosy; Male; Pigmentation Diso | 1989 |
The management of reaction in leprosy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Aspirin; Benzenesulfonates; Chloroquine | 1989 |
Bacillaemia in leprosy and effect of multidrug therapy.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy; Leprosy | 1989 |
Clofazimine in pregnancy.
Topics: Clofazimine; Female; Fetal Death; Fetal Diseases; Humans; Leprosy; Pregnancy; Pregnancy Complication | 1989 |
Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; India; Leprosy; National Health Programs; P | 1989 |
Evaluation of two multidrug regimen in hospitalised multibacillary cases.
Topics: Clofazimine; Dapsone; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; Hospit | 1989 |
Comments on an editorial by B. R. Chatterjee "On Multi-Drug Combinations in the Treatment of Leprosy".
Topics: Animals; Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Ison | 1989 |
Drug resistance and multi-drug therapy in leprosy.
Topics: Animals; Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lepr | 1989 |
Short-term multidrug therapy in multibacillary leprosy--review of 80 cases in two provinces of China (1983-1988).
Topics: Adult; China; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; L | 1989 |
Bilateral ulnar nerve abscesses in lepromatous leprosy.
Topics: Abscess; Clofazimine; Humans; Leprosy; Peripheral Nervous System Diseases; Ulnar Nerve | 1987 |
Exfoliative dermatitis after clofazimine.
Topics: Clofazimine; Dermatitis, Exfoliative; Drug Eruptions; Humans; Leprosy; Male; Middle Aged | 1985 |
A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
Topics: Adolescent; Adult; Antibodies, Bacterial; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Er | 1986 |
[Effect of rifampicin, clofazimine and dapsone in treating 296 cases of multibacillary leprosy].
Topics: Adolescent; Adult; Aged; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy; M | 1987 |
The effect of anti-reactional drugs on complement components in the type II, erythema nodosum leprosum, reaction.
Topics: Chloroquine; Clofazimine; Complement C3; Complement Factor B; Complement System Proteins; Erythema N | 1988 |
Leprosy control based on multi drug treatment in India.
Topics: Allied Health Personnel; Clofazimine; Dapsone; Data Collection; Drug Administration Schedule; Drug T | 1988 |
Multidrug therapy in hospitalised leprosy cases.
Topics: Adult; Clofazimine; Dapsone; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; | 1988 |
[Guinea: detection of leprosy and treatment by polychemotherapy].
Topics: Africa, Western; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy; Male; Rif | 1988 |
On multi-drug combinations in the treatment of leprosy.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Ethionamide; Humans; Leprosy; Rifampin | 1988 |
Paucibacillary leprosy: a comparative study of different schedules of multidrug therapy.
Topics: Adult; Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lepros | 1988 |
The killing of Mycobacterium leprae in mice by various dietary concentrations of clofazimine and ethionamide.
Topics: Administration, Oral; Animals; Clofazimine; Dose-Response Relationship, Drug; Ethionamide; Female; L | 1987 |
Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.
Topics: Adolescent; Adult; Aged; Clofazimine; Dapsone; Drug Administration Schedule; Drug Interactions; Drug | 1988 |
Diagnosis of leprosy.
Topics: Clofazimine; Dapsone; Diagnosis, Differential; Drug Combinations; Humans; Leprosy; Rifampin | 1988 |
Drug interaction during multidrug regimens for treatment of leprosy.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hu | 1988 |
[Sulfone-resistance of Mycobacterium leprae--monotherapy with diaminodiphenylsulfone--the value of triple-drug combinations].
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Leprosy; Mycoba | 1986 |
Clofazimine-resistant M. leprae.
Topics: Animals; Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mice; Mycobacterium lepr | 1986 |
Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.
Topics: Antibodies, Bacterial; Antigens, Bacterial; Clofazimine; Dapsone; Drug Therapy, Combination; Ethiona | 1986 |
Combined clofazimine- and dapsone-resistant leprosy. A case report.
Topics: Adult; Animals; Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Male; Mice; Mycob | 1986 |
[Small intestine transit anomalies in a patient with chronic abdominal pain and treated for Hansen's disease].
Topics: Abdomen; Chronic Disease; Clofazimine; Female; Gastrointestinal Motility; Humans; Intestinal Disease | 1986 |
[Therapy of leprosy today].
Topics: Clofazimine; Dapsone; Drug Resistance; Drug Therapy, Combination; Humans; Leprostatic Agents; Lepros | 1987 |
Combined chemotherapy of multibacillary leprosy of 6 months' duration.
Topics: Adolescent; Adult; Child; Child, Preschool; Clofazimine; Dapsone; Drug Therapy, Combination; Female; | 1986 |
The future of leprosy in the Dominican Republic: experience with multidrug therapy.
Topics: Adolescent; Child; Child, Preschool; Clofazimine; Dapsone; Dominican Republic; Drug Therapy, Combina | 1986 |
Preliminary results of treatment of leprosy patients in The Netherlands with daily rifampicin, dapsone and clofazimine.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Netherlands; Recurrence; Rifampin | 1986 |
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Kinetics; Leprosy; Male; | 1986 |
Clofazimine for leprosy and Mycobacterium avium complex infections.
Topics: Clofazimine; Humans; Leprosy; Mycobacterium avium; Mycobacterium Infections | 1987 |
Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
Topics: Adolescent; Adult; Brazil; Clofazimine; Dapsone; Drug Therapy, Combination; Ethionamide; Female; Hum | 1987 |
Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Topics: Adult; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Edema; Erythema Nodosum; Ethionamide; | 1986 |
Electrogustometry in Hansen's disease (study of 225 cases).
Topics: Adolescent; Adult; Ageusia; Clofazimine; Dapsone; Erythema Nodosum; Facial Paralysis; Female; Humans | 1986 |
Monitoring dapsone self-administration in a multidrug therapy programme.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Ethiopia; Female; Humans; Lepros | 1986 |
[Combination chemotherapy in leprosy].
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leprostatic A | 1986 |
[An unusual cause of parietal intestinal involvement: enteropathy due to clofazimine. Apropos of a case].
Topics: Adult; Clofazimine; Humans; Ileal Diseases; Intestinal Obstruction; Leprosy; Male; Radiography | 1986 |
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy.
Topics: Clofazimine; Dapsone; Half-Life; Humans; Kinetics; Leprosy; Rifampin | 1986 |
Leprosy and the eye: a review.
Topics: Bacterial Vaccines; Clofazimine; Dapsone; Drug Therapy, Combination; Eye Diseases; Humans; Leprosy; | 1985 |
Recent trends in chemotherapy of leprosy.
Topics: Clofazimine; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Leprostatic A | 1985 |
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates.
Topics: Animals; Antibodies, Bacterial; Clofazimine; Coombs Test; Dapsone; Drug Therapy, Combination; Enzyme | 1985 |
Polytherapy in multibacillary leprosy patients in Nepal.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Male; | 1985 |
Some observations on the pharmacology of clofazimine (B663).
Topics: Aniline Compounds; Animals; Clofazimine; Dose-Response Relationship, Drug; Feces; Humans; Isoniazid; | 1974 |
Tissue concentrations of clofazimine (B663) in man.
Topics: Adipose Tissue; Adrenal Glands; Autopsy; Clofazimine; Female; Gallbladder; Humans; Kidney; Leprosy; | 1974 |
Editorial: Problems and opportunities in the therapy of leprosy.
Topics: Clofazimine; Dapsone; Drug Resistance, Microbial; Humans; Leprostatic Agents; Leprosy; Rifampin | 1974 |
Thymus-dependent lymphocytes of peripheral blood in leprosy patients.
Topics: Adult; Aged; Animals; Blood Cell Count; Clofazimine; Dapsone; Erythema Nodosum; Erythrocytes; Humans | 1974 |
Fundamental data, methods and goals of present research on the treatment of leprosy.
Topics: Animals; Animals, Laboratory; Antitubercular Agents; Clofazimine; Dapsone; Ethionamide; Humans; In V | 1973 |
Dapsone resistance in leprosy.
Topics: Animals; Clofazimine; Dapsone; Drug Resistance, Microbial; Leprosy; Mice; Mycobacterium leprae; Rifa | 1973 |
Pharmacologic studies of clofazimine.
Topics: Administration, Oral; Animals; Clofazimine; Diet; Dose-Response Relationship, Drug; Half-Life; Human | 1974 |
The treatment of corticosteroid-dependent lepromatous patients in persistent Erythema nodosum leprosum with clofazimine.
Topics: Adrenal Cortex Hormones; Clofazimine; Erythema Nodosum; Female; Follow-Up Studies; Humans; Leprosy; | 1973 |
Management of reactions in leprosy.
Topics: Adrenal Cortex Hormones; Clofazimine; Hand Deformities, Acquired; Humans; Leprosy; Neuritis; Skin Ul | 1973 |